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ABSTRACT OF THE DISSERTATION 
Endogenous Protection in Subarachnoid Hemorrhage 
by 
Eric Milner 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2015 
Professor Gregory Zipfel, Chair 
Vasospasm-induced delayed cerebral ischemia (DCI) remains a major source of 
morbidity in patients with aneurysmal subarachnoid hemorrhage (SAH). Moreover, cognitive 
dysfunction is the primary driver of poor long-term outcome in SAH survivors; modeling such 
deficits preclinically is thus key for mechanistic and translational investigation. We hypothesized 
that activating innate neurovascular protective mechanisms by conditioning may represent a 
novel therapeutic approach against SAH-induced DCI, short-term, neurological deficits, and 
long-term neurocognitive deficits; and, secondarily, that the neurovascular protection it provides 
is mediated by endothelial nitric oxide synthase (eNOS) and hypoxia-inducible factor 1α (HIF-
1α).  
In Experiment 1,1 wild-type C57BL/6 mice were subjected to hypoxic preconditioning 
(PC) or normoxia followed 24 hours later by endovascular-perforation SAH. Neurological 
function was analyzed daily via sensorimotor scoring; vasospasm was assessed on post-surgery 
day 2. Nitric oxide availability, eNOS expression, and eNOS activity were also assessed. In a 
separate experiment, wild-type and eNOS-null mice were subjected to hypoxic PC or normoxia 
	   vii	  
followed by SAH and assessed for vasospasm and neurological deficits. All experiments were 
performed in a randomized and blinded fashion. 
PC nearly completely prevented SAH-induced vasospasm and neurological deficits. It 
also prevented SAH-induced reduction in nitric oxide availability and increased eNOS activity in 
mice with and without SAH. PC-induced protection against vasospasm and neurological deficits 
was lost in wild-type mice treated with the nitric oxide synthase inhibitor NG-nitro-L-arginine 
methyl ester and in eNOS-null mice. 
From these results, we conclude that endogenous protective mechanisms against 
vasospasm exist, are powerful, and can be induced by PC. eNOS-derived nitric oxide is a critical 
mediator of this neurovascular protection. These  “proof-of-principle” results suggest that 
conditioning represents a promising new strategy to mitigate SAH-induced neurovascular 
dysfunction. 
In Experiment 2,2 we sought to determine whether these innate protective mechanisms 
are induced by a more clinically relevant conditioning paradigm, and whether the 
cerebrovascular protection extends to non-vasospasm contributors to DCI, microthrombosis and 
microvessel dysfunction. 
Adult male mice were subjected to sham surgery, SAH surgery, or SAH and 
subsequently postconditioned with isoflurane (2% for 1h, starting 1h after surgery). Contributors 
to DCI – vasospasm of the ipsilateral middle cerebral artery, cortical microthrombosis as 
assessed by fibrinogen immunohistochemistry, and cerebrovascular vasodilatory function was 
assessed in pial vessels through a closed cranial window – were measured 3 days post-SAH. 
Neurological outcome was assessed daily. Moreover, isoflurane-induced changes in HIF-1α-–
dependent genes (glucose transporter-1, GLUT1; BNIP3) and HIF-2α-driven erythropoietin 
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(EPO) were assessed via quantitative-PCR. HIF-1α was inhibited either pharmacologically (2-
methoxyestradiol, 2ME2) or genetically in endothelial cells (EC-HIF-1-null). All experiments 
were performed in a randomized and blinded fashion. 
We found the following: first, isoflurane postconditioning markedly reduced SAH-
induced DCI in wild-type mice: vasospasm was attenuated, microthrombosis was significantly 
reduced, and microvessel function was restored. Neurological deficits were also significantly 
attenuated. Second, isoflurane modulated HIF-1α- and HIF-2α-dependent genes; these changes 
were abolished in 2ME2-treated wild-type mice and in EC-HIF-1-null mice (HIF-1α-dependent 
genes only in the latter). Third, postconditioning-induced protection against vasospasm and 
neurological deficits was attenuated in 2ME2-treated wild-type mice and in EC-HIF-1-null mice. 
In Experiment 3,3 we sought to assess whether the protection afforded by conditioning 
extended to long-term neurocognitive outcomes. Whereas rat SAH causes long-term deficits in 
learning and memory, it remains unknown whether similar deficits are seen in the mouse, a 
species particularly amenable to powerful, targeted genetic manipulation. We thus subjected 
mice to SAH and assessed long-term cognitive outcome via the Morris water maze (MWM), the 
most commonly used metric for rodent neurocognition. No significant differences in MWM 
performance (by either of two protocols) were seen in SAH versus sham mice. Moreover, SAH 
caused negligible hippocampal CA1 injury. These results undercut the potential of commonly 
used methods (of SAH induction and assessment of long-term neurocognitive outcome) for use 
in targeted molecular studies of SAH-induced cognitive deficits in the mouse. 
From these results, we concluded that endogenous protective mechanisms against DCI 
exist, are powerful, and can be induced by hypoxic PC or isoflurane postconditioning. This 
protection depends critically on eNOS-derived nitric oxide and endothelial cell–derived HIF-1α. 
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These studies provide strong evidence that conditioning – especially isoflurane postconditioning 
– represents a promising new strategy to reduce DCI after SAH. Future studies examining long-
term neurocognitive deficits should utilize rat models of SAH. 
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CHAPTER 1: Endothelial Nitric Oxide Synthase Mediates Endogenous Protection Against 
Subarachnoid Hemorrhage-Induced Cerebral Vasospasm 
 
INTRODUCTION 
Aneurysmal subarachnoid hemorrhage (SAH) occurs in ~600,000 people worldwide each 
year,4 and in ∼30,000 patients in the US.5 While it accounts for only 5-8% of strokes,4, 6 it 
accounts for a quarter of cerebrovascular deaths and of stroke-related loss of life7, 8 due to its low 
median age (52 years, versus 70-80 years for ischemic stroke4). Its case fatality remains around 
40% despite improvements in diagnosis, immediate repair of aneurysms, and improved medical 
and ICU management.4 Among SAH survivors, only 25% make a good recovery while 50% 
suffer long-term cognitive deficits9, 10 that preclude their return to work and significantly impact 
their quality of life.11 Independent risk factors for poor outcome, as determined by a multivariate 
analysis of over 3500 patients,12 include the following: older age, worse neurological status or 
elevated blood pressure upon presentation; quantity of subarachnoid blood or the presence of 
intracerebral or intraventricular blood on admission; previous SAH; or history of hypertension, 
myocardial infarction, or liver disease. In contrast, other predictors of poor outcome may be 
amenable to therapeutic intervention: these include fever, cerebral infarction, and delayed 
cerebral ischemia (DCI).12, 13 Aneurysm rupture results in markedly perturbation of intracranial 
homeostasis: intracranial pressure rapidly rises to arterial levels resulting in global cerebral 
ischemia. This acute insult is thought to lead to secondary neurological injurious processes, 
delayed cerebral ischemia and early brain injury.14 
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Delayed Cerebral Ischemia 
Delayed cerebral ischemia (DCI) is the most common and most severe form of secondary 
brain injury to develop after SAH. It occurs with a stereotypical delay, with a peak incidence of 
four to twelve days post-ictus, as a result of which it is considered the prognostic factor most 
amenable to therapeutic intervention.15 Rates of DCI have remained stable over the last decades: 
prior to 1994, 33% of patients were afflicted, and the rate in patients between 1994 and 2009 was 
29%.16 Its presence doubles the risk of poor patient outcome.17 
DCI was previously attributed directly and exclusively to cerebral vasospasm, a 
phenomenon characterized by angiographic narrowing of the large cerebral arteries 5-14 days 
post-SAH.11 Approximately two thirds of SAH patients develop angiographic vasospasm,16 and 
in one third it is moderate to severe.18 Vasospasm is thought to be a result of erythrocyte 
hemolysis in the subarachnoid space: rupture of red blood cells liberates hemoglobin and other 
molecules that initiate inflammation, production of oxygen free radicals, and an imbalance of 
vasodilatory and vasoconstrictive factors.4 Several observations support vasospasm’s central role 
in DCI: vasospasm and DCI coincide temporally;19 DCI-related symptoms occur within the 
territory of spastic arteries in many patients with vasospasm;20, 21 and targeted endovascular 
treatment of vasospasm often improves patients’ neurological status.22, 23 
The past decade has seen an evolution in understanding of DCI pathophysiology. The 
notion of vasospasm being the sole cause of DCI has been challenged by the results of clinical 
trials. First, only half of patients with angiographic vasospasm develop DCI.24 Second, drugs that 
reduce angiographic vasospasm do not improve outcome after SAH (e.g., the non-glucocorticoid 
21-aminosteroid tirilazad25 or the endothelin receptor antagonist clazosentan26). Third, the only 
drug that improves long-term outcome after SAH, the calcium antagonist nimodipine,27 has 
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minimal effect on vasospasm.4 Nonetheless, vasospasm has been repeatedly identified as an 
independent risk factor for both brain infarction and poor outcome after SAH.12, 19, 20, 28-31 
As a result of these findings, the contribution of several additional pathophysiological 
processes have been linked to DCI; these include microvessel dysfunction (i.e., microcirculatory 
autoregulatory dysfunction), microvessel thrombosis, and cortical spreading ischemia.4 In fact, 
many believe a combination of these pathological events are required to produce SAH-induced 
DCI (for review, see Macdonald4). 
Cortical microthrombosis occurs in 70% of SAH patients as assessed by a prospective 
study employing transcranial Doppler ultrasonography;32 post-mortem, it is seen in over 90% of 
patients.33 Microthrombosis correlates strongly but non-significantly with symptomatic 
vasospasm,32 correlates significantly with DCI,33 and is more severe in patients who die of DCI 
compared to those who die of rebleeding or acute hydrocephalus.34 Experimentally, 
microthrombi are seen as early as 10 minutes after SAH but peak 1-2 days after.35, 36 The 
pathophysiology of these fibrin– and activated platelet–rich thrombi37 is thought to involve a 
pro-coagulant state and altered cerebral hemodynamics. Within days of SAH, multiple measures 
of platelet activation are increased; serum levels of platelet-activating factor, von Willebrand 
factor, and tissue factor are elevated;37 and endothelial cell damage and increased expression of 
p-selectin38 all encourage platelet aggregation and conversion of fibrin to fibrinogen. Decreased 
blood flow further promotes clotting: this is due to transient ischemia secondary to increased 
intracranial pressure immediately after aneurysmal rupture, whereas days later it results from 
microvessel constriction.38 Unfortunately, treatments aimed at reducing microthrombosis have 
been disappointing: a randomized controlled trial examining the effect of aspirin in SAH patients 
was stopped because the probability of benefit became negligible.39 Moreover, a Cochrane 
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review found that antiplatelet therapy is not recommended in SAH, as a trend toward decreasing 
DCI and improving outcome was counterbalanced by increased risk of intracranial hemorrhage.27 
As such, future interventions should target either target thrombosis more selectively (in order to 
avoid hemorrhagic complications) or target thrombosis along in combination with other 
deleterious processes. 
Another contributor to DCI is microvessel dysfunction. Under normal conditions, small 
cerebral arteries, pial arterioles, and penetrating arterioles dilate or constrict in response to a 
variety of physiological stimuli. However, SAH results in increased baseline vascular tone and 
compromises many of these auto-regulatory responses in patients40, 41 and in animal models.42-44 
Altered vasoreactivity appears as early as 20 minutes after experimental SAH43 and persists for 
as long as 7 days.43 Similar to large-artery vasospasm, the underlying mechanism for this 
phenomenon appears to be a fundamental imbalance in vasodilation and vasoconstriction. 
Studies in preclinical models of SAH have documented attenuated vasodilation in response to 
adenosine, adenosine diphosphate and triphosphate, vasopressin, and nitroprusside, as well as 
increased responses to vasoconstrictive stimuli including endothelin-1 and basic pH.38 Arteriolar 
constriction was shown to correlate with microthrombosis in mouse SAH,45 supporting the 
notion that multiple deleterious processes interact to cause DCI. Indeed, alterations in 
microvascular reactivity have been linked to risk of developing DCI.46-49 Interestingly, the 
beneficial effect of nimodipine – which, as discussed above, appears to be independent of an 
effect on vasospasm – may result from attenuating the increase in myogenic tone after SAH.27, 50 
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Early Brain Injury 
The term early brain injury (EBI) refers to cerebral damage that occurring within the first 
72 hours after ictus. It is considered to be a direct consequence of aneurysm rupture, which leads 
to transient global ischemia and attendant microcirculatory disturbance, as well as direct toxicity 
of subarachnoid blood. Its two principal contributing pathophysiological processes are cerebral 
edema and cell death.14 
Cerebral edema is an independent risk factor for poor outcome (especially poor cognitive 
outcome) after SAH.51 This condition generally begins in the first several hours after SAH and 
peaks 2 to 3 days later.52 Despite affecting as many as 20% of patients53-55 and being identified as 
an independent risk factor for poor patient outcome,51 no intervention has been shown to mitigate 
it. Indeed, few studies have thus far examined its underlying pathophysiology; of those that have, 
most have identified breakdown of the blood-brain barrier (BBB) as a key contributing event.52, 
56-61 The causes of BBB disruption include widening of inter-endothelial spaces, apoptosis of 
endothelial cells and astrocytes, and degradation of extracellular matrix proteins including type 
IV collagen and tight junction proteins.38 
Another key contributor to EBI is neuronal cell death. Both direct consequences of 
aneurysm rupture – transient global ischemia and toxicity of subarachnoid blood – have been 
linked to neuronal cell apoptosis;57, 62 moreover, neuronal cell death correlates with cerebral 
edema.63 Both caspase-dependent and –independent pathways have been implicated in neuronal 
cell apoptosis after SAH.64 Of note, one protein involved in the caspase-independent apoptosis 
after SAH is Bcl-2/adenovirus E1B 19kDa-interacting protein 3 (BNIP3).65 
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Neuropsychiatric Outcomes 
While relatively few SAH survivors have significant focal neurological deficits of the 
sort that are common following ischemic stroke, long-term cognitive dysfunction is seen in 50-
60%, allowing only 33% to return to their previous level of employment despite good 
neurological outcome.66 The long-term cognitive deficits after SAH cross numerous cognitive 
domains, including memory, executive function, and language (for review, see Al-Khindi67). Of 
the memory deficits, most51, 68, 69 but not all70 studies have documented visuospatial memory as 
being particularly affected. One genetic predictor of poor cognitive outcome after SAH has been 
identified – apolipoprotein E,71, 72 a well-established risk factor for Alzheimer’s disease. 
Strikingly, no treatment has been shown to improve cognitive outcome after SAH. It is therefore 
critical to devise experimental methods to elucidate underlying mechanism and develop novel 
therapeutics for these deficits, as they are a principal driver of the long-term loss of quality of life 
in SAH survivors. 
Experimental SAH research has thus sought to model long-term neurobehavioral 
outcomes and elucidate the mechanisms responsible. Morris water maze (MWM) deficits have 
been documented in all three principal rat models (see below) 3-5 weeks after SAH,73-78 along 
with T-maze deficits in endovascular perforation SAH;77 moreover, treatment effects have been 
seen with statins75 and minocycline.77 Despite these reports in rat models of SAH, to date there 
has been no characterization of longer-term neurobehavioral deficits in mouse models of SAH. 
 
Animal Models of Subarachnoid Hemorrhage 
Multiple animal models are used to study SAH (for a review, see Titova79). These vary in 
terms of species (mouse, rat, rabbit, dog, primate) and method of inducing SAH (endovascular 
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perforation, cisterna magna injection, prechiasmatic cistern injection, clot placement); each 
produces a different constellation of SAH-induced deficits (timing and degree of vasospasm, 
BBB disruption, neuronal cell death, neurocognitive deficits, etc.). Endovascular perforation 
SAH in mice has several important advantages: the perforation is similar to the direct arterial 
damage seen with a ruptured aneurysm; cerebrovascular dysfunction occurs, at the level of the 
macrovessel and the microvessel; and, perhaps most importantly, the mouse is amenable to 
powerful genetic manipulation allowing incorporation of myriad transgenic lines to query 
mechanism precisely. One disadvantage to mouse models of SAH, however, is their apparent 
inability to recapitulate the neuronal cell death and long-term cognitive deficits seen in SAH. 
Translation of Preclinical Interventions 
The importance of including long-term outcomes in preclinical studies has been 
substantiated by disappointing results from recent therapeutic trials. Despite successfully 
reducing angiographic vasospasm after SAH, long-term patient outcome was not affected by 
administration of the non-glucocorticoid 21-aminosteroid tirilazad25 or the endothelin receptor 
antagonist clazosentan.26 One interpretation of these results is that, beyond examining short-term 
preclinical outcomes (such as early brain injury and cerebral vasospasm), the successful 
translation of putative therapies would be enhanced by evaluating longer-term neurobehavioral 
outcomes in preclinical models,80 as recommended by the Stroke Therapy Academic Industry 
Roundtable’s criteria.81 A second conclusion, given the failure of therapies targeting a single 
pathophysiological process, is that future therapies should ideally target multiple components of 
SAH-induced secondary brain injury. 
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Cerebral Conditioning 
Cerebral conditioning describes the phenomenon wherein the brain’s endogenous 
protective mechanisms against a severe injury can be induced by exposure to a mildly stressful 
stimulus (for review, see Gidday82 or Iadecola and Anrather83). Preconditioning and 
postconditioning are defined, by convention, according to whether the conditioning stimulus is 
delivered prior to or after injury, respectively. Initial investigations into cerebral conditioning 
focused on its beneficial effects on neuronal survival and function; research in recent years, 
however, has made it clear that the cerebrovasculature (as well as glial cells) is also an important 
effector of the resulting injury-tolerant phenotype.84 Support for a vascular contribution to 
cerebral conditioning comes primarily from the experimental stroke literature where conditioning 
has been shown to increase vascular patency;85 improve endothelium-dependent vasodilation86 
and cerebral blood flow;85, 87 and reduce blood-brain barrier breakdown and vasogenic edema.88, 
89 Given that the pathophysiological events that underlie DCI are primarily vascular (vasospasm, 
microcirculatory dysfunction, and microvessel thrombosis), a conditioning-based strategy 
capitalizing on endogenous protective cascades that protect the cerebrovasculature (as well as 
neurons and glia) would represent a powerful, novel intervention for SAH-induced DCI. 
Due to a variety of unique clinical and pathophysiological factors related to SAH-induced 
DCI, we1 and others90 have long hypothesized that SAH represents a patient population that is 
perfectly suited to a conditioning-based therapy. First, a large portion (approximately one-third) 
of patients predictably develop DCI after SAH.15 Second, DCI stereotypically develops in 
delayed fashion (at least 4 days post-ictus), providing an ample therapeutic window of 
opportunity. Third, a conditioning-based strategy addresses one of the principle reasons previous 
therapeutic approaches against DCI have likely failed: the targeting of a single component (often 
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vasospasm) of what is now known to be a multifactorial process (including deleterious effects on 
the cerebral microcirculation). In contrast, conditioning is inherently pleiotropic, exhibiting 
robust beneficial effects on large cerebral arteries and the cerebral microcirculation, as well as on 
other important CNS cell types including neurons and glia. Preconditioning has myriad positive 
effects on cerebral vessels and cerebral blood flow in the setting of brain ischemia, including 
maintenance of the BBB,91 reduction in cerebral edema91, improvements in cerebral blood flow 
and cerebral vessel reactivity,92 reduction in leukocyte-mediated inflammation,93 and reduction 
in endothelial cell apoptosis.94 Though the effect of conditioning on these deleterious processes 
has not been examined in SAH, the fact that each is seen following SAH raises the possibility 
that a conditioning-based intervention, via its impact on multiple injurious pathways, may 
succeed in improving outcomes where other therapies have failed. Moreover, several FDA-
approved drugs that function as conditioning stimuli,82 raising the possibility of rapid clinical 
translation should one prove efficacious in SAH. 
In the context of experimental SAH, Altay and colleagues showed that EBI after mouse 
SAH can be impacted by isoflurane postconditioning, as cerebral edema,95 neuronal cell death,96 
and neurological deficits were all reduced 24 hours post-SAH. However, these investigators 
noted that isoflurane-induced protection in SAH appeared transient, as reductions in cerebral 
edema and neurological deficits were lost at 72 hours post-SAH (neuronal cell death was not 
examined beyond 24 hours). 
The notion that the human brain can be preconditioning is substantiated by recent studies 
examining the issue of conditioning-induced protection in cerebrovascular patient populations: 
first, patients with transient ischemic attacks who later suffered ischemic strokes have smaller 
infarctions97 and lower rates of in-hospital mortality98 than patients without prior history of such 
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attacks. In the setting of SAH, one study of twelve patients found that brain tissue hypoxia 
during temporary arterial clamping for aneurysm clipping was attenuated by prior ischemic 
preconditioning (2-minute occlusion) of the proximal artery.99 More recently, in collaboration 
with Hoh and colleagues, we showed that SAH patients with pre-existing steno-occlusive 
cerebrovascular disease are less likely to develop angiographic vasospasm than those without 
such disease100 – the first evidence in humans of a potential preconditioning effect on SAH-
induced vascular dysfunction. Although these reports do not demonstrate causation, they 
intriguingly suggest that the human cerebrovasculature may in fact benefit from non-injurious 
stressors in ways similar to what has been documented in animal models. 
 
Endothelial Nitric Oxide Synthase 
Nitric oxide (NO) is a potent vasodilator whose down-regulation after SAH has been 
linked to vasospasm101 as well as to microcirculatory dysfunction43 and microvessel 
thrombosis.102 Though the link of reduced NO signaling after SAH is well established – and that 
mitigating the drop is beneficial103 – the impact of SAH on the three isoforms of NO synthase 
(NOS) remains to be elucidated fully. The effect of SAH on neuronal NOS (nNOS) and 
inducible NOS (iNOS) remains poorly understood. For endothelial NOS (eNOS), the principal 
source of NO in the vasculature, the effect is controversial: past studies are divided among 
reporting no change,104-106 an increase,107 or a decrease108 in eNOS after experimental SAH. 
Not only has the NOS-NO pathway been implicated in the pathophysiology of SAH’s 
sequelae, it has also been shown to underlie vascular conditioning in experimental cerebral 
ischemic injury. Ischemic preconditioning–induced protection against focal cerebral ischemia is 
lost with a pan-NOS antagonist but not with nNOS– or iNOS-selective pharmacologic 
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inhibitors.109 A similar loss of ischemic tolerance was noted in eNOS-null mice subjected to 
ischemic preconditioning and then focal stroke.110 
 
Hypoxia-Inducible Factor 1 
One molecule that has been identified as a mediator of isoflurane-induced conditioning, 
at least in the context of cerebral ischemia (a fundamentally different form of experimental brain 
injury), is hypoxia-inducible factor 1 (HIF-1). The central function of this molecule relates to 
maintenance of cellular homeostasis during periods of low oxygen tension – a function that has 
been strongly conserved across evolutionary lines. Under normoxic conditions, hydroxylation of 
the cytosolically-located alpha subunit (HIF-1α) by members of the prolyl hydroxylase domain 
(PHD) family leads to its rapid proteasomal degradation. Under hypoxic conditions, PHD 
activity decreases, leading to accumulation of HIF-1α. It then associates with the beta subunit 
and translocates to the nucleus, where it modulates transcription of over 100 genes.111 
In SAH, HIF-1-driven transcription appears to have either a deleterious or a salubrious 
effect depending on the timing and extent of its activation. Several studies have explored the role 
of HIF-1 in early brain injury and DCI after SAH. HIF-1 has been repeated shown to be up-
regulated following experimental SAH throughout the brain.65, 112-115 Experimental modulation of 
HIF-1, however, appears to have different effects based on the timing of intervention. Some 
studies have shown that pharmacologic inhibition 1-2 hours after experimental SAH is 
salubrious: 2ME2 administration reduced mortality114 and improved neurological outcome;114, 116 
attenuated BBB disruption and cerebral edema;113, 116 and reduced vasospasm.114 However, 
another study showed that inhibiting HIF-1 prior to (rather than after) SAH was deleterious, 
finding that YC-1 given 24 hours and 30 minutes before SAH increasing neuronal cell apoptosis 
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in hippocampal CA1 and worsening cognitive outcome as assessed by the Morris water maze.115 
Finally, one study showed that delayed up-regulation of HIF-1 was protective: administering 
desferoxamine four days after experimental SAH improved cerebral blood flow and reduced 
vasospasm.112 It is thus likely that in the context of SAH, the ultimate result of HIF-1 signaling – 
pro-survival or pro-death – is exquisitely dependent on the degree of up-regulation and its 
timing: a double-edged sword. 
Despite these severeal studies examining HIF-1α in experimental SAH, none has assessed HIF-
1α in the context of conditioning. In contrast, HIF-1α has been strongly implicated in protecting 
neurons from experimental ischemia (both in vivo and in vitro).117-121 Nonetheless, its protective 
role in the cerebrovasculature has thus far only been examined in in vitro studies with cultured 
vascular endothelial cells.94, 122, 123 As such, whether HIF-1α-mediated ischemic tolerance is 
driven (at least in part) by improved cerebral vessel function (e.g., microvessel function, cerebral 
blood flow, or vessel patency), and whether such protection extends to SAH, remain unknown. 
 
 
MATERIALS AND METHODS 
Animals: All experimental protocols were approved by the Animal Studies Committee at 
Washington University in St Louis. Three to four months old male wild-type mice (C57BL/6J) 
and homozygous eNOS−/− mice (B6.129P2-Nos3tm1Unc/J with a C57BL/6 genetic background) 
from Jackson Laboratories (Bar Harbor, ME) were used. 
Hypoxic PC: Mice were placed in a hypoxic chamber and exposed to air containing 8% 
O2/92% N2 for 4 hours with access to food and water ad libitum;124 mice were then returned to 
their cages. Normoxic controls were placed in chambers containing room air. 
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Pharmacological Inhibition of NO Synthase: To examine the effect of NO synthase 
inhibition on PC-induced neurovascular protection in SAH, wild-type mice were administered 
the pan-NO synthase inhibitor L-NG-nitroarginine methyl ester (L-NAME; 20 mg/kg 
intraperitoneally) or vehicle (normal saline) starting 1 hour before PC and continued once daily 
thereafter. 
Experimental Protocols and Groups: The first set of experiments was performed to 
assess whether hypoxic PC attenuates SAH-induced vasospasm and neurological deficits. Three 
groups of mice were used: (1) normoxia followed 24 hours later by sham surgery (Norm:Sham), 
N=11; (2) normoxia followed 24 hours later by SAH (Norm:SAH), N=16; and (3) PC followed 
24 hours later by SAH (PC:SAH), N=13. The second set of experiments was designed to 
explore the molecular pathways affected by PC and SAH. Four groups of mice were used: (1) 
Norm:Sham, N=6; (2) PC followed 24 hours later by sham surgery (PC:Sham), N=5; (3) 
Norm:SAH, N=10; and (4) PC:SAH, N=8. The third set of experiments was designed to 
examine whether pharmacological inhibition NO synthase blocks the neurovascular protective 
effects of PC in SAH. Six groups were used: (1) Vehicle:Norm: Sham, N=3; (2) 
Vehicle:Norm:SAH, N=5; (3) Vehicle:PC:SAH, N=5; (4) L-NAME:Norm:Sham, N=5; (5) L-
NAME:Norm:SAH, N=11; and (6) L-NAME:PC:SAH, N=11. For statistical power, data from 
the vehicle-treated groups were combined with data from Experiment 1 once it was determined 
that the corresponding groups were statistically similar (data not shown). The fourth set of 
experiments was designed to directly assess the contribution of eNOS in PC-induced 
neurovascular protection. Six groups of mice were used: (1) eNOS+/+ Norm:Sham, N=14; (2) 
eNOS+/+ Norm: SAH, N=12; (3) eNOS+/+ PC:SAH, N=17; (4) eNOS−/− Norm: Sham, N=12; (5) 
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eNOS−/−Norm:SAH, N=19; and (6) eNOS−/− PC:SAH, N=20. All assessments were performed 
by investigators blinded to the surgical procedure and genotypes. 
Experimental SAH: Endovascular perforation SAH was performed as 
described.125 Briefly, mice were anesthetized with isoflurane (4% induction, 1.5% maintenance), 
and a 5-0 nylon suture was introduced into the external carotid artery and advanced through the 
internal carotid artery until the internal carotid artery bifurcation. The suture was then advanced 
to induce SAH, then removed and the external carotid artery ligated. Mice in the sham surgery 
groups underwent these procedures except for suture perforation. 
Neurobehavioral Tests: Neurobehavioral outcome was examined daily using Neuroscore 
and Rotarod tests as described.125 Briefly, neurological function was graded based on a motor 
score (0 to 12) that evaluated spontaneous activity, symmetry of limb movements, climbing, 
balance, and coordination and a sensory score (4 to 12) that evaluated body proprioception and 
vibrissae, visual, and tactile responses. Balance and coordination were assessed by performance 
on the Rotarod (Rotamex-5; Columbus Instruments, Columbus, OH). Mice were pretrained on 
the Rotarod 1 day before surgery. Latency on 3 trials of 180 seconds was averaged daily. 
Vasospasm Assessment: Vasospasm assessment was performed on post-surgery Day 2 
through cerebrovascular casting, as described.125 Briefly, mice were anesthetized and 
transcardially perfused with phosphate-buffered saline, 10% formalin, and 3% gelatin–India ink 
solution. Brains were removed, SAH was graded as described,125 and blood vessels imaged 
under a microscope using a charge-coupled device camera. The narrowest diameter within the 
first 1000 µm of the middle cerebral artery was measured to assess vasospasm. 
NO Availability Assay: NO availability was determined using DAF-2DA (fluorophore 
4,5-diaminofluorescein-2-diacetate; EMD Chemicals, Gibbstown, NJ) as described.107 Briefly, 
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brain lysates were incubated with 50 µmol/L DAF-2DA for 30 minutes at 22°C in the dark. The 
reaction mixture was excited at 495 nm and emission read at 515 nm in a spectrophotometer 
(Biotek, Winooski, VT). 
Western Blot: Western blots were performed as described.126 Briefly, brains were 
harvested 48 hours after sham or SAH surgery. Tissue from the hemisphere ipsilateral to 
endovascular perforation was lysed in a buffer containing 10 mmol/L 4-(2-hydroxyethyl)-1-
piperazine-ethanesulfonic acid, 5 mmol/L MgCl2, 1 mmol/L dithiothreitol, 2 mmol/L 
ethylenediaminetetra-acetic acid, 2 mmol/L ethylene glycol bis(β-aminoethyl ether)-N,N,N′,N′-
tetra-acetic acid, 1 mmol/L phenylmethylsulfonyl fluoride, 1% Triton X-100, 0.5 mmol/L 
sodium orthovanadate, 0.1 µmol/L okadaic acid, 25 mmol/L β-glycerophosphate, and protease 
inhibitor cocktail (Sigma). The following primary antibodies were used: mouse antieNOS (BD 
Biosciences), rabbit anti-inducible nitric oxide (iNOS; Santa Cruz Biotechnology), mouse anti-
neuronal nitric oxide synthase (nNOS; Santa Cruz Biotechnology), and mouse anti-α-tubulin 
(Sigma). Blots were subsequently incubated with anti-mouse or anti-rabbit horseradish 
peroxidase-conjugated IgG and visualized using an enhanced chemiluminescence kit (BioRad). 
eNOS Activity Assay: NO synthase activity assay was performed as 
described.127 Briefly, brain tissue ipsilateral to endovascular perforation was lysed in a buffer 
containing 20 mmol/L 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid, pH 7.4, 320 
mmol/L sucrose, 1 mmol/L dithiothreitol, and protease inhibitor cocktail. Brain lysates were 
incubated for 30 minutes in an assay buffer containing 20 mmol/L 4-(2-hydroxyethyl)-1-
piperazine-ethanesulfonic acid, pH 7.4, 60 µmol/L [3H]-L-arginine 1 mCi/mL, 1 mmol/L 
ethylenediaminetetra-acetic acid, 1.2 mmol/L CaCl2, and 2.5 mmol/L β-reduced nicotinamide-
adenine dinucleotide phosphate. Samples were also incubated in this mixture along with 10 
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µmol/L L-NG-monomethyl arginine (competitive inhibitor of all NO synthase isoforms) or 10 
µmol/L 1-(2-trifluoromethylphenyl) imidazole (selective inhibitor of nNOS and 
iNOS).19 Protein was removed by centrifugation and supernatant was passed through 
Dowex50WX-8 columns (Na+ form) and eluted. The radioactivity of [3H]-citrulline was 
measured within eluates by scintillation spectrometry (Packard Instrument Company, Meriden, 
CT). The activity in the mixture containing L-NG-monomethyl arginine was considered 
background and subtracted from the activity of the mixture containing 1-(2-
trifluoromethylphenyl) imidazole to obtain activity specific to eNOS. 
Statistical Analyses: Data are presented as the mean±SEM and were analyzed by 
analysis of variance followed by Newman-Keuls multiple comparison method unless otherwise 
indicated. P<0.05 was considered statistically significant. 
 
 
RESULTS 
PC Attenuates SAH-Induced Vasospasm 
Significant vasospasm (27%±6% vessel constriction, P<0.05) was noted 2 days after 
SAH in nonpreconditioned mice (Figure 1). In contrast, preconditioned mice did not develop 
significant vasospasm (7%±6% vessel constriction, P>0.05; Figure 1). Hemorrhage grade 
(nonpreconditioned=3.9; preconditioned=3.7) and mortality (nonpreconditioned=5.8%, 
preconditioned=7.1%) were not significantly different between SAH groups. 
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PC Improves Neurological Outcome After SAH 
SAH led to significant neurobehavioral deficits by Neuroscore and Rotorod latency test 
(P<0.05) in nonpreconditioned mice (Figure 2). These neurobehavioral deficits were 
significantly attenuated in preconditioned mice (P<0.05; Figure 2). 
 
PC Attenuates SAH-Induced Reduction in NO Availability 
NO availability was assessed 72 hours after PC (48 hours after sham or SAH surgery). 
SAH reduced NO availability by 42%±20% (P<0.05) in nonpreconditioned mice (Figure 3). 
However, in preconditioned mice, NO availability was unchanged after SAH (i.e., SAH-induced 
reduction in NO availability was prevented; Figure 3). PC also increased NO availability in 
sham-operated mice by 69%±34% (P<0.05). 
 
NO Synthase Inhibition Blocks PC-Induced Neurovascular Protection in SAH 
NO synthase inhibition with L-NAME was found to (1) reduce baseline middle cerebral 
artery diameter by 12%±4% (P=0.03); (2) have no impact on the degree of vasospasm after SAH 
(29%±5% vessel constriction in vehicle-treated versus 32%±8% vessel constriction in L-NAME-
treated nonpreconditioned mice, P=0.7); and (3) completely block PC-induced protection against 
vasospasm (66%±15% vasospasm protection in vehicle-treated versus −25%±23% vasospasm 
protection in L-NAME-treated mice, P=0.003) and neurological deficits by Neuroscore and 
Rotarod (P>0.05) after SAH (Figure 3). Hemorrhage grade was not significantly different 
between L-NAME-treated SAH groups (nonpreconditioned=3.5; preconditioned=4.1); however, 
mortality was different (nonpreconditioned=31%; preconditioned=0%, P<0.05 by Fisher exact 
test). 
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PC Selectively Increases eNOS Expression After SAH 
eNOS, nNOS, and iNOS expression was assessed 72 hours after PC (48 hours after sham 
or SAH surgery). PC increased eNOS expression by 1.4-fold (P=0.04) in SAH-operated mice but 
had no effect on nNOS (P=0.39) or iNOS (P=0.40; Figure 4). SAH alone did not alter eNOS, 
nNOS, or iNOS expression (Figure 4). 
 
PC Increases eNOS Activity After SAH 
eNOS activity was assessed 72 hours after PC (48 hours after sham or SAH surgery). PC 
increased eNOS activity by 2.3-fold (P<0.05) in sham-operated mice and by 1.6-fold (P<0.05) in 
SAH-operated mice (Figure 4). SAH alone did not alter eNOS activity (Figure 4). 
 
eNOS Contributes to PC-Induced Protection Against Vasospasm and Neurological Deficits 
After SAH 
To directly assess the role of eNOS in PC-induced neurovascular protection, a separate 
group of wild-type (eNOS+/+) and eNOS-null (eNOS−/−) mice was examined. SAH caused 
significant (P<0.05) vasospasm in both eNOS+/+ (21%±5% constriction) and eNOS−/− (24%±5% 
constriction) mice (Figure 5A). As expected, SAH-induced vasospasm was nearly completely 
prevented (94%±19% vasospasm reduction; P<0.05) in preconditioned eNOS+/+ mice (Figure 
5A–B). However, vasospasm protection by preconditioning was largely absent (24%±20% 
vasospasm reduction) in eNOS−/− mice (Figure 5A–B). A commensurate loss in PC-induced 
neurobehavioral protection (by Neuroscore) was also found in eNOS−/− mice (Figure 5C). 
Rotarod testing was not performed because naïve eNOS−/− mice had substantial Rotarod deficits 
at baseline (data not shown). Hemorrhage grade (eNOS+/+ nonpreconditioned mice=3.2; 
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eNOS+/+ preconditioned mice=3.7; eNOS−/− nonpreconditioned mice=3.1; and 
eNOS−/− preconditioned mice=3.7) and mortality (eNOS+/+ nonpreconditioned mice=6.7%; 
eNOS+/+ preconditioned mice=10.3%; eNOS−/− nonpreconditioned mice=5.0%; and 
eNOS−/−preconditioned mice=4.7%) were not significantly different between SAH groups. 
 
 
DISCUSSION 
In the present study, we established the existence of endogenous protection against SAH-
induced neurovascular deficits by demonstrating that preconditioned mice develop almost no 
vasospasm and exhibit reduced neurological deficits after SAH. This finding demonstrates, for 
the first time, that PC is efficacious in a fundamentally different form of stroke, SAH, and 
provides support to the evolving concept of vascular PC for brain ischemia.82, 90 Moreover, we 
demonstrated that the neurological protection afforded by PC in the setting of SAH is due, in 
part, to decreased vasospasm, a well-recognized risk factor for poor outcome after SAH. 
With respect to the molecular mechanism underlying PC-induced vasospasm protection, 
we examined NO given its influence on vascular function103 and its role in both vasospasm 
pathophysiology103, 107 and PC-induced neuroprotection.103, 128, 129 We found that NO availability 
decreased after SAH and that PC increased NO levels in both sham– and SAH-operated mice. 
Both results are consistent with past studies,82, 90, 103 although the latter has not been previously 
reported in the setting of SAH. We also demonstrated that inhibition of NO synthesis abolished 
the protective effect of PC on SAH-induced vasospasm and neurological dysfunction. This result 
is similar to that reported in studies examining PC in the setting of cerebral ischemia88, 109, 128 and 
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neonatal hypoxia–ischemia.129, 130 Collectively, these data strongly suggest that NO synthase-
derived NO is a critical mediator of PC-induced neurovascular protection in SAH. 
To identify the NO synthase isoform that contributes to the observed protective effect of 
PC, we examined the effect of PC on the expression of all 3 NO synthase isoforms (eNOS, 
nNOS, and iNOS) in the setting of SAH. Given that eNOS expression was selectively 
upregulated after PC and that eNOS is the primary enzymatic source of NO in cerebral 
vessels130 and the most strongly implicated NO synthase isoform in vasospasm 
pathophysiology103 and vascular PC,109, 128, 130 we next examined the effect of PC on eNOS 
activity. Our finding that PC increased eNOS activity in both sham and SAH mice, when 
coupled with the aforementioned observation that NO synthase-derived NO is critical for PC-
induced neurovascular protection, suggests that the vasculoprotective effects of PC likely occur 
through increased NO secondary to a persistent up-regulation in eNOS. 
Our findings in eNOS-null mice provided further support for this hypothesis. That PC-
induced abrogation of vasospasm and neurobehavioral deficits in wild-type mice was lost in 
eNOS-null mice (although the degree of vasospasm and neurological deficits after SAH was 
similar between the 2 groups when not preconditioned) indicates that the innate protective 
mechanisms by which PC reduces SAH-induced neurovascular deficits are dependent, to a 
significant extent, on eNOS. More broadly for the field of PC, our results lend additional support 
to the notion that eNOS is a key contributor to PC-induced neuroprotection. Other studies of PC-
induced vasculoprotection in focal ischemic stroke have advanced similar conclusions regarding 
the participation of eNOS.109, 131 
The effect of SAH on eNOS expression and/or activity is controversial. We found no 
effect of SAH on either metric, but previous studies report no change,104-106 a reduction,108 or an 
	   21	  
increase107 in eNOS expression after SAH. Similarly, SAH was found to either have no effect105, 
132, on phosphorylated eNOS (at Ser1177, one of many active forms of eNOS132) or an 
increase.106-108 In addition, our experiments identified what could be considered a discrepancy 
between eNOS activity (no change) and NO availability (decreased) in response to SAH. Several 
possibilities could explain this observation. First, it is possible that a SAH-induced decrease in 
eNOS activity actually occurred in vivo but was undetected by our ex vivo assay. This could 
occur if availability of one or more substrates (e.g., L-arginine) or cofactors (e.g., reduced 
nicotinamide-adenine dinucleotide phosphate), which were artificially provided in our ex vivo 
assay, became limited; or if the endogenous NO synthase inhibitor asymmetrical dimethyl L-
arginine was upregulated by SAH.103 Second, it is possible that NO availability was decreased 
after SAH despite unchanged eNOS activity. For example, this could occur through NO 
scavenging by oxyhemoglobin133 and/or leukocytes134 present in the subarachnoid space. In 
either case, PC-induced changes appear significant enough to overwhelm these factors and 
restore NO production to pre-SAH levels. 
Some limitations of our study should be noted. First, PC was administered before SAH. 
This was by design, because our study was conceived as a “proof-of-concept” one to establish 
whether endogenous protective mechanisms against vasospasm are present and thus permit their 
exploration. Studies examining the efficacy of post-SAH conditioning paradigms have already 
been initiated in our laboratory. Second, although the clinical applicability of hypoxia as a 
preconditioning stimulus may be difficult to envision, several pharmacological agents with 
known PC effects are available for future testing.135 Third, because no animal model fully 
recapitulates human SAH, it is essential to validate our findings in complementary SAH models. 
Fourth, although vasospasm is a major contributor to delayed cerebral ischemia, other factors 
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may also contribute (for review, see Macdonald et al.8); whether PC also positively affects these 
factors will require future study. Fifth, our study does not exclude a contribution from nNOS or 
iNOS; however, it is very unlikely that either plays a major role given that neither was 
upregulated after PC in the setting of SAH. Finally, we recognize that the neurological deficits 
documented in our SAH model are likely multifactorial and that the observed neuroprotection 
could be explained in part by beneficial effects of PC on reducing neuronal 
apoptosis,136 inflammation,137 and/or blood–brain barrier breakdown.91 In fact, the robustness of 
the PC-induced protection noted in our study suggests a multifaceted underlying mechanism; 
therapeutic strategies for SAH that target several deleterious cascades would likely have great 
potential for clinical efficacy. 
In conclusion, results from this “proof-of-principle” study indicate that powerful 
endogenous protective mechanisms against vasospasm exist, that they can be activated by a 
preconditioning stimulus, and that their underlying mechanism is at least partly dependent on 
eNOS-derived NO. Further studies to more fully elucidate the innate molecular pathways that 
prevent vasospasm, and to examine the therapeutic potential of postconditioning strategies for 
SAH, are warranted. 
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Figure 1: PC attenuates SAH-induced vasospasm. 
Mice underwent hypoxic PC or normoxia (Norm) followed 24 hours later by SAH or sham 
surgery. On post-surgery Day 2, mice were perfused with gelatin–India ink. A, Representative 
images of gelatin-India ink casted vessels. Vasospasm of the middle cerebral artery (arrow) was 
evident in SAH- vs. sham-operated mice; PC attenuated this vasospasm. Scale bar: 200 microns. 
B, Vessel diameter in the proximal middle cerebral artery ipsilateral to suture perforation was 
determined. Data indicate mean±SEM *P<0.05. 
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Figure 2: PC improves neurological outcome after SAH.  
Mice underwent hypoxic PC or normoxia (Norm) followed 24 hours later by SAH or sham 
surgery. Neurobehavioral assessment was performed on Days 0 to 2 by Neuroscore (A) and 
Rotarod latency (B) tests. Data indicate mean±SEM with Rotarod results normalized to Day 0. 
*P<0.05 vs. Norm:Sham; #P<0.05 vs. Norm:SAH. Statistical analysis was performed by 
repeated-measures analysis of variance of rank transformed variables followed by a Fisher's least 
significant difference post-hoc test. 
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Figure 3: NO synthase-derived NO mediates PC-induced protection against neurovascular 
dysfunction after SAH. 
Mice underwent hypoxic PC or normoxia (Norm) followed 24 hours later by SAH or sham 
surgery. NO availability was quantified by fluorometric detection of DAF-2DA on brain 
homogenates obtained on post-surgery Day 2 (A). Data indicate mean±SEM *P<0.05 vs. 
Norm:Sham; #P<0.05 vs. Norm:SAH. In a separate experiment, mice were administered the pan-
NOS inhibitor L-NAME and subjected 1 hour later to hypoxic PC or normoxia (Norm) followed 
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24 hours later by SAH or sham surgery. Vasospasm was assessed in the middle cerebral artery 
on post-surgery Day 2 by the gelatin–India ink casting method (B). *P<0.05, n.s. P>0.05 by 
analysis of variance and Newman-Keuls multiple comparison test; neurobehavioral assessment 
was performed on Days 0 to 2 by Neuroscore (C) and Rotarod latency (D) tests. *P<0.05 vs 
Norm:Sham. Data indicate mean±SEM. 
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Figure 4: PC increases eNOS expression and activity. 
Mice underwent hypoxic PC or normoxia (Norm) followed 24 hours later by SAH or sham 
surgery. eNOS, nNOS, and iNOS expression was assessed by Western blot and eNOS activity 
was assessed by [3H]L-arginine to [3H]L-citrulline conversion, both performed on brain 
homogenates obtained on post-surgery Day 2. (A) Representative immunoblot images (N 
indicates normoxia); (B) quantification data of eNOS, nNOS, and iNOS expression normalized 
to α-tubulin; and (C) quantitative data of eNOS activity. Data indicate mean±SEM (B) *P<0.05, 
n.s. P>0.05 by Student's t-test; (C) *P<0.05 vs. Norm:Sham, #P<0.05 vs. Norm:SAH by analysis 
of variance and Newman-Keuls multiple comparison test. 
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Figure 5: PC-induced protection against vasospasm and neurological deficits after SAH is 
dependent on eNOS.  
Wild-type (eNOS+/+) and eNOS-null (eNOS−/−) mice were subjected to hypoxic PC or normoxia 
(Norm) followed 24 hours later by SAH or sham surgery. Vasospasm was assessed on post-
surgery Day 2 by the gelatin–India ink casting method and shown as absolute diameter changes 
(A) or normalized to the extent of SAH-induced vasospasm in normoxic mice (B). Neurological 
outcome was evaluated on Days 0 to 2 by Neuroscore (C). Data represent mean±SEM. (A) 
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*P<0.05, n.s. P>0.05 by analysis of variance and Newman-Keuls multiple comparison test; (B) 
*P<0.05 for vasospasm protection in eNOS−/− vs. eNOS+/+ mice using Student's t-test; (C) 
*P<0.05 vs. eNOS−/− Sham by repeated-measures analysis of variance of rank transformed 
variables and Fisher's least significant difference post-hoc test. 
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CHAPTER 2: Isoflurane Postconditioning Reduces Subarachnoid Hemorrhage–Induced 
Delayed Cerebral Ischemia via Hypoxia-Inducible Factor 1α 
 
INTRODUCTION 
Delayed cerebral ischemia (DCI) is the most common and most severe form of secondary 
brain injury to develop after aneurysmal subarachnoid hemorrhage (SAH). Occurring after a 
stereotypical delay (peak incidence 4-12 days post-ictus), it is thus the most likely to be 
amenable to therapeutic intervention.15 The hallmark of DCI is cerebrovascular pathology: 
Cerebral vasospasm is a primary driver of DCI, as supported by the following observations: 
vasospasm and DCI coincide temporally;19 DCI-related symptoms occur within the territory of 
spastic arteries in many patients with vasospasm;20, 21 and targeted endovascular treatment of 
vasospasm often improves patients’ neurological status.22, 23 Vasospasm has also been repeatedly 
identified as an independent risk factor for both brain infarction and poor outcome after SAH.4, 
12, 19, 20, 28-30 In recent years, however, several additional pathophysiological processes have been 
linked to DCI; these include microcirculatory autoregulatory dysfunction, microvessel 
thrombosis, and cortical spreading ischemia.4 Indeed, many believe a combination of these 
pathological events are required to produce SAH-induced DCI (for review, see Macdonald4). 
Cerebral conditioning describes the phenomenon wherein the brain’s endogenous 
protective mechanisms against a severe injury can be induced by exposure to a mildly stressful 
stimulus (for review, see Gidday82 or Iadecola and Anrather83). Preconditioning and 
postconditioning are defined, by convention, according to whether the conditioning stimulus is 
delivered prior to or after injury, respectively. Initial investigations into cerebral conditioning 
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focused on its beneficial effects on neuronal survival and function; research in recent years, 
however, has made it clear that the cerebrovasculature (as well as glial cells) is also an important 
effector of the resulting injury-tolerant phenotype.84 Support for a vascular contribution to 
cerebral conditioning comes primarily from the experimental stroke literature where conditioning 
has been shown to increase vascular patency,85 improve endothelium-dependent vasodilation86 
and cerebral blood flow,85, 87 and reduce blood-brain-barrier breakdown and vasogenic edema.88, 
89 Given that the pathophysiological events that underlie DCI are primarily vascular (vasospasm, 
microcirculatory dysfunction, and microvessel thrombosis), a conditioning-based strategy 
capitalizing on endogenous protective cascades that protect the cerebrovasculature (as well as 
neurons and glia) would represent a powerful, novel intervention for SAH-induced DCI. We 
were the first to apply such a strategy to the field of SAH, showing that hypoxic preconditioning 
(i.e., brief exposure to hypoxia prior to induction of SAH) prevented vasospasm and markedly 
improved neurological outcome. We also showed that this protection depended critically on 
endothelial nitric oxide synthase (eNOS), a molecule whose dysregulation after SAH is well 
known to contribute to vasospasm138 and has also been linked to microcirculatory dysfunction43 
and microvessel thrombosis.102 
Due to a variety of unique clinical and pathophysiological factors related to SAH-induced 
DCI, we1 and others90 have long hypothesized that SAH represents a patient population that is 
perfectly suited to a conditioning-based therapy. First, a large portion (approximately one-third) 
of patients predictably develop DCI after SAH.15 Second, DCI stereotypically develops in 
delayed fashion (at least 4 days post-ictus), providing an ample therapeutic window of 
opportunity. Third, a conditioning-based strategy addresses one of the principle reasons previous 
therapeutic approaches against DCI have likely failed: the targeting of a single component (often 
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vasospasm) of what is now known to be a multifactorial process (including deleterious effects on 
the cerebral microcirculation). In contrast, conditioning is inherently pleiotropic, exhibiting 
robust beneficial effects on large cerebral arteries and the cerebral microcirculation, as well as on 
other important CNS cell types including neurons and glia. 
As a follow-up to our proof-of-concept study examining pre-SAH delivery of a 
conditioning stimulus (hypoxia), we next turned our attention towards translating this concept to 
a post-SAH conditioning paradigm. Preliminarily, we noted that transient focal ischemia initiated 
soon after experimental SAH afforded strong neurovascular protection; however, we also found 
that isoflurane alone (included as an anesthetic control for ischemic postconditioning) provided 
similarly strong neurovascular protection. Given this volatile anesthetic’s much greater clinical 
translatability as a conditioning stimulus (as compared to potentially deleterious approaches such 
as hypoxia or ischemia), we sought to characterize the breadth and extent of isoflurane-induced 
neurovascular protection in SAH, and to define its underlying mechanism.  
One molecule that has been identified as a mediator of isoflurane-induced conditioning, 
at least in the context of cerebral ischemia (a fundamentally different form of experimental brain 
injury), is hypoxia-inducible factor 1 (HIF-1). The central function of this molecule relates to 
maintenance of cellular homeostasis during periods of low oxygen tension – a function that has 
been strongly conserved across evolutionary lines. Under hypoxic conditions, the alpha subunit 
(HIF-1α) accumulates, associates with the beta subunit, and translocates to the nucleus, where it 
modulates transcription of over 100 genes.111 Whereas HIF-1α has been strongly implicated in 
protecting neurons from experimental ischemia (both in vivo and in vitro),117-121 its protective 
role in the cerebrovasculature has thus far only been examined in in vitro studies with cultured 
vascular endothelial cells.94, 122, 123 As such, whether HIF-1α-mediated ischemic tolerance is 
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driven (at least in part) by improved cerebral vessel function (e.g., microvessel function, cerebral 
blood flow, or vessel patency) remains unknown. Moreover, while HIF-1α has been examined in 
several reports employing experimental models of SAH,112-116 none has assessed HIF-1α in the 
context of conditioning. 
We thus sought to determine whether a clinically relevant conditioning paradigm (i.e., 
isoflurane postconditioning) protects against experimental SAH–induced DCI and neurological 
deficits, and whether HIF-1α contributes to this protective phenotype. To obtain direct, causal 
data, we employed complementary HIF-1α-directed interventions including pharmacologic 
inhibition of HIF-1α via 2-methoxyestradiol (2ME2) administration and genetic inhibition of 
vascular endothelial HIF-1a knockout mice via a Cre-Lox approach. 
 
 
MATERIALS AND METHODS 
Ethical Statement: All experimental protocols were approved by the Animals Studies 
Committee at Washington University in St. Louis and complied with the NIH Guide for the Care 
and Use of Laboratory Animals and with Washington University Department of Comparative 
Medicine guidelines. 
Study Design: Allocation of animals to a given experiment and experimental subgroup 
was performed randomly prior to each experiment: one experimenter numbered tails and another 
experimenter assigned mice according to these numbers. All data were collected by 
experimenters blinded to experimental group. Each experiment included a minimum of three 
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independent replications (i.e., cohorts subjected to surgery on separate days, with every 
experimental group represented in each cohort). 
Experimental animals were housed in an AAALAC-accredited facility in temperature– 
and humidity-controlled rooms with a 12-hour light-dark cycle. Mice were housed 5 to a cage 
and had ad libitum access to lab chow and tap water. A total of 276 mice were used at 12-14 
weeks of age (24-30 g): 203 male C57BL/6 mice (Jackson Labs, Bar Harbor, ME) and 67 male 
endothelial cell HIF-1α null (EC HIF-1α–/–); the latter were bred by crossing Tie2-Cre and HIF-
1αfl/fl transgenic mice lines (both on C57BL/6 background; both Jax) as described:139 Tie2-Cre-
positive, HIF-1αfl/fl mice were used. In addition, a total of 6 male mice derived from crossing 
Tie2-Cre and ROSA26 reporter mice (background: 129X1/SvJ; Jax) were used to assess cell-
specific expression of Tie2-Cre: tomato-red fluorescence is changed to green fluorescence with 
Cre expression. Only male mice were used due to known neuroprotective effects of estrogen.140 
Sample sizes: When comparing vasospasm, cortical microthrombosis, and neurological 
outcome, based on our previous studies1, 141 we estimated 80% power to detect a 20% difference 
between groups with N=14 per group based on a one-way analysis of variance (ANOVA) model 
at a significance of 5%. When comparing microvascular reactivity and qPCR, based on previous 
studies142 and the literature44, 143 we estimated 80% power to detect a 25% difference between 
groups with N=5-8 per group based on a one-way ANOVA model at a significance level of 5%. 
Endovascular perforation SAH was performed per established protocol.1, 141 Briefly, a 5-0 
blunted nylon suture was advanced from the left external carotid into the internal carotid artery 
and advanced distally to the point of feeling resistance at its bifurcation into the anterior and 
middle cerebral arteries (MCA). For SAH, the suture was advanced further to cause perforation. 
For sham, the suture was removed without advancement. Mice were allowed to recover in a 
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heated incubator and then returned to their home cages. Surgeries were performed in the late 
morning and early afternoon in the Animal Surgery Core at Washington University. 
Isoflurane postconditioning was performed in an anesthetic induction chamber, as 
described with modification.95 Briefly, mice were placed in the chamber perfused with 2% 
isoflurane in room air for 1 h; temperature was maintained via a homeothermic blanket. Controls 
were placed in the same chamber perfused only by room air. In experiments assessing isoflurane-
induced transcriptional changes, these same parameters were used. In a subset of mice, 
physiological parameters were examined 2 h after surgery in three groups: sham surgery, SAH 
surgery, SAH surgery + isoflurane postconditioning (1 h of 2% isoflurane in room air beginning 
1 h after SAH surgery). Arterial pH, pCO2, pO2, hematocrit, and hemoglobin were assessed via a 
femoral artery catheterization. 
Gross neurological outcome was assessed in the morning prior to surgery and daily 
thereafter via sensorimotor scoring per established protocol.1, 141 Briefly, a motor score (0–12; 
comprising spontaneous activity, symmetry of limb movement, climbing, and balance and 
coordination) and a sensory score (4–12; comprising proprioception plus vibrissae, visual, and 
tactile responses) were added together. 
SAH-induced DCI was assessed 3 d after surgery according to three components: 
cerebral vasospasm was assessed per established protocol1, 141 via pressure-controlled casting 
with gelatin–India ink solution and measurement of the proximal MCA. Second, microvessel 
reactivity was assessed per established protocol.142 Briefly, a closed cranial window was made to 
allow visualization of leptomeningeal arterioles; vasodilation to three stimuli was examined: 
physiological hypercapnea; superfusion of the endothelium-dependent vasodilator acetylcholine 
(ACh, 100 µM); and superfusion of the endothelium-independent vasodilator S-Nitroso-N-
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acetylpenicillamine (SNAP; 500 µM, both Sigma-Aldrich, St. Louis, MO). Third, cortical 
microthrombosis was assessed via 3,3'-diaminobenzidine (DAB) staining for fibrinogen as 
described with modification.126 Briefly, following transcardial perfusion with heparinized PBS, 
brains were removed and sliced coronally at 50 µm. Floating sections were incubated with 0.3% 
H2O2 in PBS for 10 min, washed three times in PBS for 5 min, blocked (blocking buffer: 0.1% 
Triton-X100, 0.2% dry mild, and 1% BSA in PBS) on a shaker for 1 h, then incubated with 
rabbit anti-fibrinogen antibody (1:1000 in blocking buffer; abcam, Cambridge, MA) at 4°C 
overnight. After three further washes, sections were incubated with goat–anti-rabbit biotinylated 
secondary antibody (1:1000; BioRad, Hercules, CA) for 1 h, washed three times, and incubated 
with VECTASTAIN Elite ABC Kit solution (Vector Laboratories, Inc., Burlingame, CA), 
washed three times, then transferred to peroxidase substrate solution (1 tab DAB, 40µL H2O2, 
and 10µL NiSO4 in 40mL ddH2O). After ~2.5 min, tissues were transferred to PBS to stop the 
peroxidase reaction and mounted onto glasses slides, dried, and cover-slipped. Percent coverage 
of ipsilateral parietal cortex was determined using the threshold function in ImageJ (NIH, 
Bethesda, MD). 
The HIF inhibitor 2-methoxyestradiol (2ME2, Sigma) was administered at a dose of 15 
mg/kg IP once daily (vehicle: normal saline), with the first dose given prior to isoflurane 
exposure or surgery. This dose was chosen based on a previous report144 showing its efficacy in 
preventing HIF-mediated transcriptional effects in adult rodent brain. 2ME2 is known to inhibit 
both HIF-1α and HIF-2α.145 
Quantitative real-time PCR (qPCR) was performed as described.143 Briefly, following 
transcardial perfusion with heparinized PBS, cortex was rapidly frozen on dry ice followed by 
extraction of messenger RNA using TRIzol (Life Technologies, Grand Island, NY) and reverse 
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transcription (of 2 µg mRNA) with the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster, CA). qPCR of HIF-1α and HIF-2α transcriptional targets was performed 
using the ABI 7500 in default mode with SYBR Green Master Mix (Applied Biosystems) using 
the following primers (Integrated DNA Technologies, Coralville, IA): HIF-1α: forward GAA 
CAT CAA GTC AGC AAC GTG, reverse TTT GAC GGA TGA GGA ATG GG; erythropoietin 
(EPO): forward GAG GTA CAT CTT AGA GGC CAA G, reverse TCT TCC ACC TCC ATT 
CTT TTC C; glucose transporter 1 (GLUT1): forward GAT TGG TTC CTT CTC TGT CGG, 
reverse CCC AGG ATC AGC ATC TCA AAG; BCL2/adenovirus E1B 19 kd-interacting protein 
(BNIP3): forward ACC ACA AGA TAC CAA CAG AGC, reverse CGA CTT GAC CAA TCC 
CAT ATC C; and glyceraldehyde 3-phosphate dehydrogenase (GAPDH): forward CTT TGT 
CAA GCT CAT TTC CTG G, reverse TCT TGC TCA GTG TCC TTG C. Messenger RNA 
levels were calculated relative to GAPDH via the ΔCt method and are expressed relative to naïve 
controls. 
Cre-mediated expression was assessed by crosses of Tie2-Cre mice with floxed ROSA26 
reporter mice per established protocols.146 Briefly, following transcardial perfusion with 
heparinized PBS, brains were removed and sliced coronally at 50 µm. Sections were counter-
stained with DAPI then mounted on glass slides and cover-slipped with VectaShield (Vector 
Laboratories, Burlingame, CA). 
Statistical Analysis: Data represent individual animals and are expressed as means±SEM. 
Following testing for normality, vasospasm, microthrombosis, microvessel reactivity, and qPCR 
were analyzed by ANOVA followed by Tukey’s HSD test. Following testing for normality, 
Neuroscore was analyzed by repeated measures ANOVA followed by Newman-Keuls multiple 
comparison. Statistical significance was set at p < 0.05. 
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RESULTS 
Postconditioning Attenuates SAH-Induced Cerebrovascular Dysfunction 
To determine the temporal window for postconditioning-induced protection, we exposed 
mice to isoflurane at various times after SAH surgery. Mortality was not significantly different 
between groups (6.1% in non-postconditioned SAH mice versus 6.9% in postconditioned SAH 
mice). However, substantial DCI protection was noted: postconditioning beginning at 15 min, 1 
h, or 3 h after SAH eliminated SAH-induced vasospasm; this protection was lost when 
postconditioning began at 6 h (Fig 6A and B; p<0.05, omnibus ANOVA). Given the robust 
protection seen with postconditioning starting at 1 h, this time point was used for subsequent 
experiments. Other vascular contributors to DCI were also significantly improved by 
postconditioning. Extensive cortical microthrombosis was noted in MCA-territory cerebral 
cortex after SAH, which was significantly reduced by postconditioning (Fig 7A and B; p<0.05, 
omnibus ANOVA). SAH-induced microvessel function was also restored by postconditioning 
(Fig 8). Cerebrovascular function was significantly impaired after SAH as assessed by responses 
to physiologic hypercapnia, as well as to local application of the endothelium-dependent and 
endothelium-independent dilators ACh and SNAP, respectively, compared to sham animals. 
Postconditioning fully restored the vasodilatory responses to hypercapnia and SNAP (Fig 8; 
p<0.05, omnibus ANOVA) and produced a strong trend towards improving ACh-induced 
vasodilation, though this did not reach our predetermined threshold for statistical significance 
(Fig 8; p=0.062, omnibus ANOVA). Together, these results show that postconditioning after 
mouse SAH can positively impact multiple contributors to cerebrovascular-mediated DCI, 
establishing it as a novel therapeutic approach for this devastating secondary brain injury. 
 
	   39	  
Postconditioning Improves Neurological Outcome After SAH 
To determine whether the breadth of protection afforded by postconditioning extends 
from the cerebrovasculature to functional outcomes, neurological status was assessed before 
SAH and daily thereafter via sensorimotor scoring. SAH caused significant neurological deficits, 
which were markedly attenuated by isoflurane postconditioning beginning at 15 min, 1 h, or 3 h, 
but not at 6 h, after ictus (Fig 9; p<0.05, omnibus repeated measures ANOVA). The 
neurovascular protection afforded by isoflurane postconditioning was not related to isoflurane-
induced physiological changes, as no significant differences in arterial pH, pCO2, pO2, O2 
saturation, hematocrit, and hemoglobin were noted across experimental groups (Table 1). 
 
Pharmacologic Inhibition of HIF Prevents Isoflurane’s Transcriptional Effect and 
Postconditioning’s Neurovascular Protection 
Next, we sought to determine whether this SAH-tolerant phenotype is dependent on HIF. 
In naïve WT mice, isoflurane exposure significantly modulated the HIF transcriptional targets 
EPO, GLUT1, and BNIP3 in a time-dependent manner. Administration of 2ME2 (a 
pharmacologic inhibitor of HIF-1α and HIF-2α) significantly attenuated these effects for each 
gene (Fig 10A; p<0.05, omnibus ANOVA). The same dose of 2ME2 eliminated the protection 
afforded by isoflurane postconditioning against SAH-induced vasospasm (Fig 10B; p<0.05, 
omnibus ANOVA) and neurological deficits (Fig 10C; p<0.05, omnibus repeated measures 
ANOVA). Together, these results show that isoflurane modulates HIF-driven transcription, and 
that pharmacologic inhibition of this transcriptional response abolishes the protection against 
SAH-induced neurovascular dysfunction afforded by isoflurane postconditioning. 
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Genetic Deletion of Endothelial HIF-1α Inhibits Isoflurane’s Transcriptional Effect and 
Postconditioning’s Neurovascular Protection 
To test our hypothesis that HIF-1α-driven transcriptional activation in endothelial cells in 
response to isoflurane postconditioning drives the observed vasculoprotective phenotype, we 
generated endothelial cell–specific HIF-1α knockout mice. Endothelial cell expression of Cre in 
our Tie2-Cre mice was verified by crossing them with ROSA26 reporter mice and examining 
cerebral microvascular fluorescence in the brains of their progeny. As shown in Figure 11, green 
fluorescence – indicative of Cre expression – was seen throughout the cerebrovascular 
endothelium of Cre-positive mice (Fig 11Av to viii), but the endothelium of Cre-negative mice 
fluoresced red (Fig 11Ai to iv). In naïve EC HIF-1α–/– mice, isoflurane exposure did not 
significantly affect transcription of the HIF-1α targets GLUT1 and BNIP3; by contrast, 
transcription of EPO was significantly increased (Fig 11B; p<0.05, omnibus ANOVA), which is 
consistent with a known role of vascular HIF-2α (retained in these mice) in regulating EPO.147 
Genetic deletion of endothelial HIF-1α eliminated the protection afforded by isoflurane 
postconditioning against SAH-induced vasospasm (Fig 11C; p<0.05, omnibus ANOVA) and 
neurological deficits (Fig 11D; p<0.05, omnibus repeated measures ANOVA). Collectively, 
these results provide causal evidence that vascular endothelium–derived HIF-1α is critical for 
isoflurane’s transcriptional effect and the neurovascular protection afforded by its use as a 
postconditioning treatment. 
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DISCUSSION 
DCI is the most common and potentially treatable cause of secondary neurological injury 
following SAH;15 among patients affected by DCI, up to one-third experience poor outcome or 
death.4 We1 and others90 have hypothesized that DCI may represent an ideal clinical scenario for 
a conditioning-based therapy due to several factors: 1) the predictability of ischemia – after a 
stereotypical delay of many days – in a significant fraction of this clinical population; 2) the 
severity of DCI and its contribution to poor patient outcome; and 3) the multifactorial nature of 
DCI that could be positively affected by a conditioning stimulus. Whereas the terms DCI and 
cerebral vasospasm have traditionally been used interchangeably, the last decade has seen an 
expanded appreciation for the contribution to DCI of other pathophysiological processes 
including cortical microthrombosis, microvessel dysfunction, and cortical spreading depression 
(for review, see Macdonald, 20144). 
We thus sought to determine whether postconditioning – with a clinically relevant 
stimulus and at a clinically relevant time point – could mitigate the deleterious effects of DCI 
following experimental SAH. Our main findings are as follows: First, we demonstrated that a 
brief “dose” of isoflurane, administered 15 min, 1 h, or 3 h after SAH (but not 6 h later) 
strikingly attenuated the SAH-induced vasospasm and neurological deficits observed days later. 
This shows that a clinically relevant paradigm of isoflurane postconditioning provides strong 
neurovascular protection in SAH. Notably, the afforded protection is dependent on timing of the 
conditioning stimulus, similar to findings in experimental ischemic stroke.148 Second, we found 
that isoflurane postconditioning markedly attenuated two additional contributors to DCI, cortical 
microthrombosis and microvessel dysfunction. This shows that isoflurane provides broad 
vascular protection, at not only the macro-vessel level (vasospasm) but also at the 
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microcirculatory level; this breadth enhances its translational potential. Third, we documented 
that isoflurane exposure modified HIF target gene expression and that this transcriptional 
modulation was prevented by pharmacologic and genetic inhibition of HIF in an internally 
consistent manner. Specifically, pharmacologic inhibition of HIF-1α and HIF-2α with 2ME2 
prevented isoflurane-induced modulation of all HIF target genes (GLUT1, BNIP3, and EPO), 
while selective genetic deletion of HIF-1α in vascular endothelial cells prevented isoflurane-
induced modulation of HIF-1α target genes (GLUT1 and BNIP3) but not HIF-2α target genes 
(EPO).147 Fourth, we demonstrated that pharmacologic and genetic inhibition of HIF reversed the 
protective phenotypes we identified in postconditioned mice. Specifically, pharmacologic 
inhibition of HIF-1 and HIF-2 with 2ME2 administration blocked isoflurane-induced 
neurovascular protection in SAH, as did selective genetic deletion of HIF-1α in vascular 
endothelial cells. Taken together, these data indicate that a clinically relevant paradigm of 
isoflurane postconditioning strongly inhibits macro- and microvascular contributors to DCI, that 
this multifaceted vascular protection is mediated via endothelial-cell-derived HIF-1α, and that 
the robust vascular protection afforded by isoflurane postconditioning leads to markedly 
improved neurological outcome after SAH. 
Our group was the first to show that SAH may be amenable to a conditioning strategy: 
we showed that hypoxic preconditioning significantly attenuated SAH-induced neurovascular 
dysfunction in the mouse, and that this protection was critically dependent on eNOS-derived 
nitric oxide.1 Subsequently, Altay and colleagues showed that early brain injury after mouse 
SAH can be impacted by isoflurane postconditioning, as cerebral edema,95 neuronal cell death,96 
and neurological deficits were all reduced at 24 h post-SAH. However, in contrast to our finding 
of sustained neurovascular protection at 72h post-SAH, these investigators noted that isoflurane-
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induced protection in SAH appeared transient, as reductions in cerebral edema and neurological 
deficits were lost at 72 h post-SAH (neuronal cell death was not examined beyond 24 h). This 
discrepancy between the two studies in the sustainability of isoflurane-induced protection has a 
variety of potential explanations including variations between our respective endovascular 
perforation techniques (4-0 versus 5-0 suture used herein), our neurological assessment scales (6-
point versus 8-point sensorimotor scoring used herein), our vascular endpoints (BBB disruption 
versus vasospasm, microthrombosis, and microvessel dysfunction used herein), or a 
combination. Regardless, the present study significantly extends upon these initial findings in 
several important ways: 1) we demonstrated isoflurane postconditioning produced sustained 
neurological protection in SAH; 2) we found that it protected against three separate contributors 
to DCI that act at both the macro-vessel level (vasospasm) and micro-vessel level 
(microthrombosis and microvessel dysfunction); 3) we identified an extended therapeutic 
window of opportunity (3 h post-SAH); and 4) we identified vascular endothelium–derived HIF-
1α as an essential factor in the neurovascular protection afforded by isoflurane postconditioning. 
Isoflurane conditioning has been shown to reduce neuronal cell injury and neurological 
deficits in a variety of acute cerebrovascular conditions including neonatal hypoxia-ischemia,149, 
150 ischemic brain injury,121, 151-154 and intracerebral hemorrhage.155 Notably, several groups have 
linked the brain protection afforded by isoflurane to HIF-1α.119, 121 Isoflurane increases HIF-
1α119, 121, 156 and HIF target genes;119, 121 isoflurane protects against OGD-induced neuronal cell 
death in a HIF-1α-dependent fashion;121 and administration of pharmacologic agents that 
augment HIF-1α provide protection against experimental cerebral ischemia154, 157 (e.g., DMOG, a 
prolyl hydroxylase inhibitor that augments HIF-1α but also inhibits numerous other enzymes;158 
and deferoxamine, an iron chelator that indirectly inhibits prolyl hydroxylase and augments HIF-
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1α but also inhibits other iron-dependent enzymes159 and stabilizes the mitochondrial 
permeability transition pore160). Importantly, none of these studies established a causal role of 
HIF-1α in the protection afforded by isoflurane in animal models of acute cerebrovascular injury, 
nor have they linked HIF-1α to isoflurane-induced vascular protection. In the present study, we 
provide such evidence. First, we establish that isoflurane-induced protection extends to SAH, a 
fundamentally different form of acute cerebrovascular injury. Second, utilizing complementary 
pharmacologic and genetic techniques we show that vascular endothelium–derived HIF-1α is a 
key mediator of this protection – the first to directly implicate HIF-1α in the brain protection 
afforded by isoflurane in any in vivo paradigm of acute cerebrovascular injury. Third, we show 
that HIF-1α mediates not only isoflurane-induced neural protection but also isoflurane-induced 
vascular protection – the first study to our knowledge to make this important link. 
Our preclinical results are substantiated by recent studies examining the issue of 
conditioning-induced protection in patients with cerebrovascular disease: first, patients with 
transient ischemic attacks who later suffered ischemic strokes have smaller infarctions97 and 
lower rates of in-hospital mortality98 than patients without prior history of such attacks. More 
recently, in collaboration with Hoh and colleagues, we showed that SAH patients with pre-
existing steno-occlusive cerebrovascular disease are less likely to develop angiographic 
vasospasm than those without such disease:100 the first evidence in humans of a potential 
preconditioning effect on SAH-induced vascular dysfunction. Although these reports do not 
establish causation, they intriguingly suggest that the human cerebrovasculature may in fact 
benefit from non-injurious stressors in ways similar to what has been documented in animal 
models. 
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Our study raises several questions that warrant further investigation. First, by what 
mechanism(s) does isoflurane activate HIF-1α in the context of postconditioning in SAH? Here, 
several possibilities exist including isoflurane up-regulation of HIF-1α via phosphorylation by 
phosphatidyl inositol phosphate 3-kinase, S-nitrosylation by nitric oxide, and reduced 
hydroxylation by prolyl hydroxylases (for review, see Hieber et al.161) Second, by what 
downstream molecular effector(s) does HIF-1α reduce the brain’s susceptibility to SAH? One 
possibility is that the HIF-1α-mediated protection afforded by isoflurane is the consequence of 
HIF-1α’s effect on gene expression and protein synthesis in its cell of origin, the vascular 
endothelium. If so, several observations suggest that eNOS could be the downstream mediator: 
1) eNOS is expressed in vascular endothelial cells and can be modulated by HIF-1α;154, 162 2) 
eNOS has been linked to vasospasm,138 cortical microthrombosis,102 and microvessel 
dysfunction;44 and 3) neurovascular protection afforded by a different conditioning paradigm 
(brief hypoxia 24hr prior to SAH) is critically dependent on eNOS. Another possibility (though 
not mutually exclusive from HIF-1α’s transcriptional effects in vascular endothelial cells) is that 
one or more HIF-1α-driven secreted proteins (e.g., vascular endothelial growth factor, which has 
been linked to vasospasm protection in at least one study163) exerts paracrine protective effects 
on neighboring cells. Third, is the neurovascular protection afforded by isoflurane 
postconditioning present across SAH model systems (endovascular perforation, cisterna magna 
injection, and pre-chiasmatic injection), species (lissencephalic versus gyrencephalic), gender 
(male versus female), age (young versus old), comorbidities (hypertension, diabetes, etc.), and 
outcome measures (short-term versus long-term)? These cross-validation experiments are critical 
if isoflurane and/or HIF-1α-based therapies are to be considered for translational studies, and are 
strongly advocated by the Stroke Therapy Academic Industry Roundtable.81 
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Another important issue to be examined is the impact of HIF-1α up-regulation by SAH 
itself, which several groups have documented in various animal models of SAH,112, 114-116 versus 
that induced by isoflurane postconditioning as we documented in the present study. In this 
instance, timing, severity, and sustainability of HIF-1α up-regulation and its downstream 
transcriptional effects may matter greatly since pharmacologic inhibition of HIF-1α activation 
has been shown to be protective or deleterious depending on the specific experimental 
conditions, in a variety of acute cerebrovascular injury paradigms including ischemic stroke (for 
review, see Singh et al., 2012164) and SAH.112, 114-116 This “double-edged sword” impact of HIF-
1α must be fully understood in the setting of SAH if HIF-1α-based therapies are to be pursued in 
translational studies. Alternatively, it may be that the therapeutic index for pharmacologic 
manipulation of HIF-1α is too narrow to be a viable target for SAH therapeutics, in which case 
isoflurane itself (or potentially other agents including different inhalational anesthetics or 
alternate classes of anesthetics) may prove a more promising intervention against SAH-induced 
DCI and the resultant morbidity and mortality. 
In conclusion, this study demonstrates that isoflurane has beneficial vasculoprotective 
effects on experimental SAH–induced DCI, and that this protection is critically dependent on 
endothelial cell HIF-1α-driven gene transcription. This is a novel and exciting finding given that 
isoflurane is already FDA-approved for use in this patient population and that administration of 
isoflurane at a clinically applicable dose and at a clinical relevant time point provided robust 
protection against several contributors to DCI. Moreover, the stereotypical delay between SAH 
and DCI provides a meaningful therapeutic window of opportunity for an isoflurane-based 
postconditioning strategy. 
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Figure 6: Postconditioning eliminates SAH-induced vasospasm. 
Mice underwent sham surgery; subarachnoid hemorrhage (SAH) surgery; or SAH surgery 
followed by isoflurane postconditioning (2% for 1 h, SAH-postC) starting 15 minutes, 1h, 3h, or 
6 h after surgery. On post-surgery day 3, pressure-controlled cerebrovascular casting was 
performed with gelatin–India ink. A. Representative images of the middle cerebral artery (MCA) 
ipsilateral to endovascular perforation. B. Vessel diameter of the ipsilateral MCA was assessed. 
N=6 sham, N=10 SAH, N=16 SAH-postC-15', N=12 SAH-postC-1h, N=14 SAH-postC-3h, 
N=15 SAH-postC-6h. Data represent mean±SEM. *p<0.05 by ANOVA. 
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Figure 7: Postconditioning attenuates SAH-induced cortical microthrombosis. 
Mice underwent sham surgery, subarachnoid hemorrhage (SAH) surgery, or SAH surgery 
followed 1 h later by isoflurane postconditioning (2% for 1 h, SAH-postC). On post-surgery day 
3, brains were subjected to fibrinogen immunohistochemistry. A. Representative images of 
parietal cortex ipsilateral to endovascular perforation. B. Cortical microthrombosis was 
determined as percent coverage of ipsilateral parietal cortex. N=15 sham, N=16 SAH, N=12 
SAH-postC. Data represent mean±SEM. *p<0.05, **p<0.01 by ANOVA. 
 
 
	   49	  
 
Figure 8: Postconditioning reverses SAH-induced microvessel dysfunction. 
Mice underwent sham surgery, subarachnoid hemorrhage (SAH) surgery, or SAH surgery 
followed 1 h later by isoflurane postconditioning (2% for 1 h, SAH-postC). On post-surgery day 
3, microvessel function was examined through an open cranial window. Pial arteriolar 
vasodilatory responses to hypercapnia (CO2), the endothelium-dependent vasodilator 
acetylcholine (ACh), and the endothelium-independent vasodilator S-nitroso-N-acetyl-
penicillamine (SNAP) were assessed. N=7 per group. Data represent mean±SEM. *p<0.05 by 
ANOVA. 
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Figure 9: Postconditioning improves neurological outcome after SAH. 
Mice underwent sham surgery; subarachnoid hemorrhage (SAH) surgery; or SAH surgery 
followed by isoflurane postconditioning (2% for 1 h, SAH-postC) starting 15 minutes, 1h, 3h, or 
6 h after surgery. Neurobehavioral assessment was performed on post-surgery days 0-3 via 
sensorimotor scoring. N=6 sham, N=10 SAH, N=16 SAH-postC-15', N=12 SAH-postC-1h, 
N=14 SAH-postC-3h, N=15 SAH-postC-6h (the same animals as were assessed for vasospasm in 
Figure 6). Data represent mean±SEM. *p<0.05 vs. sham, #p<0.05 vs. SAH, by repeated 
measures ANOVA and Newman-Keuls multiple comparison test. 
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Table 1: Physiological Parameters in Arterial Blood. 
Group n pH pCO2 
(mmHg) 
pO2 
(mmHg) 
Hematocrit 
(%) 
Hemoglobin 
(g/dL) 
Sham 4 7.40 ± 0.001 41.5 ± 1.1 90.7 ± 3.4 43.6 ± 0.5 14.2 ± 0.3 
SAH 6 7.37 ± 0.001 42.9 ± 1.9 87.9 ± 0.9 442. ± 0.5 14.3 ± 0.3 
SAH-postC 5 7.39 ± 0.001 41.1 ± 1.9 90.7 ± 4.2 44.1 ± 0.6 14.7 ± 0.2 
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Figure 10: HIF-1 mediates isoflurane-induced transcription and postconditioning-induced 
neurovascular protection after SAH. 
A. Mice were administered vehicle or the HIF-1 inhibitor 2-methoxyestradiol (2ME2), exposed 
to isoflurane (2% for 1 h), sacked at 3 h, 24 h, or 72 h, and cortical tissue was subjected to 
quantitative real-time PCR. Data represent mean±SEM. *p<0.05 vs. naïve, #p<0.05 vs. time-
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matched isoflurane-only by ANOVA. N=6 mice per group. B-C. Mice were administered vehicle 
and subjected to sham surgery; were administered vehicle and subjected to subarachnoid 
hemorrhage (SAH) surgery followed 1 h later by isoflurane postconditioning (2% for 1 h, SAH-
postC); or administered 2ME2 and subjected to SAH-postC. On post-surgery day 3, pressure-
controlled cerebrovascular casting was performed with gelatin–India ink (B). Data represent 
mean±SEM. *p<0.05 by ANOVA. Neurobehavioral assessment was performed on post-surgery 
days 0-3 via Neuroscore (C). N=8 sham, N=10 SAH, N=10 SAH-postC, N=9 SAH-postC-
2ME2. Data represent mean±SEM. *p<0.05 vs. sham, #p<0.05 vs. SAH, ‡p<0.05 vs. SAH-
postC-veh by repeated measures ANOVA and Newman-Keuls multiple comparison test. 
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Figure 11: Endothelial HIF-1 mediates isoflurane-induced transcription and postconditioning-
induced neurovascular protection after SAH. 
Endothelial cell hypoxia-inducible factor 1 null (EC HIF-1–/–) mice were bred using a Cre-lox 
system. A. Tie2-Cre mice were bred to ROSA26 reporter mice. Note green fluorescence in 
cerebrocortical endothelial cells (indicating Tie2-Cre expression) but not in other cell types (red) 
in the brains of the offspring. B. EC HIF-1–/– mice were subjected to normoxia (naïve) or 
isoflurane (2% for 1 h), sacked at 3 h or 24 h, and cortical tissue was subjected to quantitative 
real-time PCR. N=5 mice per group. Data represent mean±SEM. *p<0.05 vs. naïve by ANOVA. 
C-D. EC HIF-1–/– mice underwent sham surgery, subarachnoid hemorrhage (SAH) surgery, or 
SAH surgery followed 1 h later by isoflurane postconditioning (2% for 1 h, SAH-postC). On 
post-surgery day 3, pressure-controlled cerebrovascular casting was performed with gelatin–
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India ink. C. Vessel diameter of the ipsilateral middle cerebral artery was assessed. N=21 sham, 
N=20 SAH, N=11 SAH-postC. Data represent mean±SEM. *p<0.05 by ANOVA. C. 
Neurobehavioral assessment was performed on post-surgery days 0-3 via Neuroscore. Data 
represent mean±SEM. *p<0.05 vs. sham by repeated measures ANOVA and Newman-Keuls 
multiple comparison test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published in: Annals of Clinical and Translational Neurology. 2015 Apr;2(4):325-37. doi: 
10.1002/acn3.170. Epub 2015 Feb 21.2 
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CHAPTER 3: Endovascular Perforation Subarachnoid Hemorrhage Fails to Cause Morris Water 
Maze Deficits in the Mouse 
 
INTRODUCTION 
Aneurysmal subarachnoid hemorrhage (SAH) is a neurologically devastating disease that 
affects 6-7 people per 100,000 each year. Mortality remains near 50%;11 while relatively few 
SAH survivors have significant focal neurological deficits of the sort that are common following 
ischemic stroke, long-term cognitive dysfunction is seen in 50–60%, allowing only 33% to return 
to their previous level of employment despite good neurological outcome,66 The long-term 
cognitive deficits after SAH cross numerous cognitive domains, including memory, executive 
function, and language (for review, see Al-Khindi, 201067). Of the memory deficits, most51, 68, 69 
but not all70 have documented visuospatial memory as being particularly affected. Strikingly, no 
treatment has been shown to improve cognitive outcome after SAH. It is therefore critical to 
devise experimental methods to elucidate underlying mechanism and develop novel therapeutics 
for these deficits, as they are a principal driver of the long-term loss of quality of life in SAH 
survivors. 
Experimental models of SAH vary in species used and in method of induction; each has 
its unique advantages and disadvantages.79 A key benefit of mouse models is the ability to 
incorporate myriad transgenic lines to query mechanism precisely. This is directly relevant to 
SAH, as apolipoprotein E (ApoE) and haptoglobin genotypes have been identified as genetic risk 
factors for poor patient outcome, the former being independently associated with poor cognitive 
outcome after SAH.71, 72 
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The importance of including long-term outcomes in preclinical studies has been 
substantiated by disappointing results from recent therapeutic trials. Despite successfully 
reducing angiographic vasospasm, long-term patient outcome was not affected by administration 
of the non-glucocorticoid 21-aminosteroid tirilazad25 or the endothelin receptor antagonist 
clazosentan.26 It may be that, beyond examining short-term preclinical outcomes (such as early 
brain injury and cerebral vasospasm), the successful translation of putative therapies would be 
predicted by evaluation of longer-term neurobehavioral outcomes in preclinical models,80 as 
recommended by the Stroke Therapy Academic Industry Roundtable’s criteria.81 
Experimental SAH research has thus sought to model long-term neurobehavioral 
outcomes and elucidate the mechanisms responsible. Morris water maze (MWM) deficits have 
been documented in all three principal rat models 3-5 weeks after SAH,73-78 along with T-maze 
deficits in endovascular perforation SAH;77 moreover, treatment with statins75 and minocycline77 
has decreased SAH-induced cognitive deficits. Notably, a strong correlation was seen in rat SAH 
between MWM performance and neuronal cell counts in hippocampus at 5 weeks.73 
Despite these reports in rat models of SAH, to date there has been no characterization of 
longer-term neurobehavioral deficits in mouse models of SAH. We thus undertook to 
characterize cognitive deficits in the most commonly used mouse model of SAH, endovascular 
perforation, using the gold standard of spatial learning, the MWM. 
 
 
MATERIALS AND METHODS 
Animals: All experimental protocols were approved by the Animals Studies Committee 
at Washington University in St. Louis and complied with the Guide for the Care and Use of 
	   58	  
Laboratory Animals; the Public Health Service Policy on Humane Care and Use of Laboratory 
Animals; and Washington University Department of Comparative Medicine guidelines. Mice 
were housed in an AAALAC-accredited facility in temperature- and humidity-controlled rooms 
with a 12-hour light-dark cycle. Mice were allowed ad libitum access to standard chow and 
autoclaved tap water. A total of 250 male wild-type C57BL/6 mice (Jackson Labs, Bar Harbor, 
ME) were used starting at 12–14 weeks of age (24–30 g). Allocation to experimental group was 
performed prior to the beginning of each experiment: tails were numbered by one experimenter 
and another experimenter assigned mice randomly according to these numbers. All data were 
collected by experimenters blinded to experimental group. The study included 5 independent 
experiments (summarized in Table 2): in Experiment 1, mice were subjected to SAH, given 3 
days of fluid support, and assessed for cerebral vasospasm on post-SAH day 3. In Experiment 2, 
mice were subjected to SAH, given 3 days of fluid support, and assessed via Place MWM. 
Significant long-term mortality was seen, and so attempts were made to improve survival, first 
by extending fluid support to post-operative day 7 (Experiment 3) and second by not only 
extending fluid support to 7 days but also administering ampicillin165 (Experiments 4 and 5). A 
more sensitive MWM protocol, the Learning Set task, was employed in a subset of studies 
(Experiment 4, cohort 2, and Experiment 5). TBI was used as a positive control (Experiment 5). 
Endovascular Perforation SAH: For Experiments 1-4, endovascular perforation SAH was 
performed as described.1, 141 Briefly, mice were anesthetized with isoflurane (4% induction, 1.5% 
maintenance) and a midline neck incision was made. The external carotid artery (ECA) was 
isolated, and through it a 5-0 blunted nylon suture was introduced into the internal carotid artery 
(ICA). The suture was advanced distally until resistance was felt at the bifurcation of the ICA 
into the anterior and middle cerebral arteries. Advancing the suture a further 5 mm caused 
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perforation and SAH. The suture was immediately removed and the ECA was ligated. Sham-
operated mice were subjected to all surgical procedures except that, upon feeling resistance at the 
ICA bifurcation, the suture was removed without advancement. Cerebral vasospasm was 
assessed on post-SAH day 3 via pressure-controlled casting with gelatin–India ink solution. 
Controlled Cortical Impact Traumatic Brain Injury: In Experiment 5, 
electromagnetically-controlled cortical impact model of TBI was performed as previously 
described.166 Briefly, mice were anesthetized with isoflurane (4% induction, 2% maintenance) 
and placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA). A 1-cm midline scalp 
incision was made and a left craniotomy was performed over the parietotemporal cortex using a 
5-mm trephine (Meisinger, Neuss, Germany) attached to an electric drill (Foredom, Bethel, CT). 
The impact device was mounted on the stereotaxic frame at an angle of 15° and moved 3.0 mm 
anterior to lambda and 2.7 mm left of midline, inside the craniotomy. Zero depth was 
determined, the tip was cocked, and the device was lowered using the stereotaxic arm to set a 
depth of impact of 2 mm. TBI was triggered via Matlab (The Mathworks, Natick, MA). A 6-mm 
plastic disc was glued to the skull over the craniotomy and the incision was sutured. Sham-
operated mice were subjected to all surgical procedures except for TBI. 
Fluid Support: In all cases, mice were administered 0.5 ml of 10% dextrose in normal 
saline IP twice daily. In Experiments 1 and 2, support was provided on post-operative days 0-3, 
as previously described.141 In Experiment 3, this regimen was extended to post-operative day 7. 
For Experiments 4 and 5, mice were administered 50 mg/kg ampicillin in dextrose in normal 
saline twice daily on post-operative days 0-3, followed on post-operative days 4-7 by dextrose in 
normal saline. 
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Neuroscore: For all experiments, gross neurologic function was assessed on post-
operative days 0-3, 7, and 12 via sensorimotor scoring as previously described.1, 141 Briefly, 
neurological function was graded based on a motor score (0 to 12) that evaluates spontaneous 
activity, symmetry of limb movements, climbing, and balance and coordination; and a sensory 
score (4 to 12) that evaluates body proprioception and vibrissae, visual, and tactile responses. For 
Experiments 2-4, data presented include sham-operated mice; SAH mice that survived long term 
and were able to complete MWM testing (survival group); and mice that survived initially (i.e., 
at least 3 d after SAH), but either died before MWM testing or were excluded owing to being 
unable to complete MWM testing (mortality group, SAH-mort). 
Morris Water Maze:  
For all MWM experiments, a 100-cm pool was filled with water rendered opaque with 
non-toxic white paint. A 10-cm escape platform was made to either protrude 1 cm above the 
surface of the water (Cued trials) or was submerged 1 cm (Place and Learning Set trials). Mice 
were released from one of four cardinal drop points. If the mouse found the platform, it was 
allowed to sit for 15 seconds before removal; if the mouse failed to find the platform, it was 
placed on the platform for 15 seconds. An overhead camera recorded swim paths. SMART 
software (San Diego Instruments, San Diego, CA, USA) analyzed escape latency, swim 
distances, and swim speeds for all trials. All experiments were conducted by a single investigator 
(EM) blinded to experimental groups. 
Two different protocols were used. For the Place MWM,166, 167 mice were given 4 trials 
per days, one from each drop point. On post-SAH days 13-15, mice were subjected to 4 trials of 
the Cued task (visible platform) with a single platform location. On days 18-22, mice were 
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subjected to the Place task with a single (hidden) platform location. On day 23, a 30-second 
Probe trial was performed. 
For the Learning Set MWM (modified from Hartman et al., 2005167), each day mice 
consisted of 8 blocks of 2 consecutive trials. On post-SAH day 13, mice were subjected to the 
Cued task: a new (visible) platform location was used for each block, and mice were dropped 
from diametrically opposite the platform. On days 14-20, mice were subjected to the Learning 
Set task with a new (hidden) platform position each day. For block 1, the same distant drop point 
was used; for blocks 2-8, drop points were counter-balanced for near-far. On days 15-21, mice 
were subjected to a 30-second Probe trial (i.e., a probe trial ~16 hours after completing the 
previous day’s task). 
Mice were disqualified from MWM testing if they failed to swim to the visible platform 
during Cued training. This was due to either an inability to learn or to complete the procedural 
aspects involved, including staying above water for 4 or 16 daily trials (Place and Learning Set, 
respectively) and lifting onto the elevated platform; or due to deficits in vision or motivation to 
escape the water. Sensorimotor data from these mice are included along with mice that died prior 
to MWM testing (mortality group; see Neuroscore section above). 
Neuronal Cell Counting: After completing the final Probe trial, mice were sacrificed and 
transcardially perfused with heparinized PBS. Brains were post-fixed overnight in 4% 
paraformaldehyde in PBS, equilibrated in 30% sucrose, sectioned coronally at 50 µm, and 
stained with cresyl violet. Unbiased stereology was performed using Stereo Investigator (MBF 
Bioscience, Williston, VT). A single investigator blinded to treatment assessed 3-5 hippocampal 
sections taken at 600-µm intervals; morphologically intact neurons were counted in hippocampal 
CA1 from midline to the lateral extent of the superior limb of the angular gyrus. 
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Statistical Analysis: Data are expressed as means ± SEM. Mortality was analyzed by 
Kaplan-Meier estimator. Following testing for normality, Neuroscore and MWM performance 
were analyzed by repeated measures analysis of variance followed by Newman-Keuls multiple 
comparison. Probe performance, CA1 neuronal cell count, and CA1 volume were first assessed 
for normality and then analyzed by unpaired t-test. Correlation between neuronal cell counts and 
MWM performance was analyzed by least-squares linear regression. Statistical significance was 
set at p < 0.05.  
 
 
RESULTS 
Short-term SAH outcome 
Acute SAH mortality (0-3 days) was similar in Experiments 1-4 (p=0.80, Kaplan-Meier 
estimator). Marked cerebral vasospasm was noted 3 days after SAH (arrows) in Experiment 1 
(Figure 12A-B; p<0.05, t-test); cerebral vasospasm was not assessed in Experiments 2-4 due to 
the post-mortem nature of this assessment in the mouse. Significant sensorimotor neurological 
deficits were noted 1-3 days after SAH in Experiments 1-4 (Figures 12C, 13A, 14A, 15A), and 
were similar across SAH groups. Overall, these data are in line with our previous reports1, 141 and 
demonstrate the short-term reproducibility of our endovascular perforation SAH mouse model. 
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Long-term SAH outcome 
Mortality 
Delayed SAH mortality (after day 3) was noted in all long-term experiments (Figure 
12D; p=0.0010, p=0.0152, p=0.0053 for Experiments 2-4, respectively, Kaplan-Meier estimator). 
A significant reduction in delayed SAH mortality was noted in Experiment 4 versus Experiment 
2 (Figure 12D; p=0.048, Kaplan-Meier estimator). Together, these data indicate that long-term 
SAH survival can be increased by extending fluid support from 3 to 7 days and adding antibiotic 
prophylaxis, but nonetheless long-term SAH survival remains suboptimal. 
 
Neurological deficits 
Mild but statistically significant neurological deficits were noted in long-term SAH 
survivors (Figure 13A, 14A, 15A; p<0.001, p<0.05, p<0.01 for Experiments 2-4, respectively, 
omnibus repeated measures ANOVA). Mice that survived to day 3 (the typical point of 
assessment for vasospasm-driven delayed cerebral ischemia) but did not complete the MWM 
(due to either delayed mortality or disqualification) evinced dramatically more severe 
neurological deficits than mice that survived and were able to complete the MWM. In total, these 
data demonstrate that SAH survivors had mild sensorimotor deficits, whereas mice that were 
excluded from long-term assessments (MWM and unbiased stereology) had severe sensorimotor 
deficits. 
 
Morris Water Maze 
Performance in the Place MWM was similar between SAH and sham groups (Figure 
13B-C, 14B-C, 15B-C). No significant differences were seen in the Cued task (visible platform) 
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(p=0.36, p=0.46, p=0.27, Experiments 2-4, respectively, omnibus repeated measures ANOVA). 
No significant differences were seen in the Place task (hidden platform) (p=0.77, p=0.11, p=0.85, 
Experiments 2-4, respectively, omnibus repeated measures ANOVA). No significant differences 
were seen in Probe trial performance: Time spent in the target quadrant was similar (p=0.15, 
p=64, p=0.65 for Experiments 2-4, respectively, t-test) and time spent in the target area was 
similar (p=0.61, p=10, p=0.17 for Experiments 2-4, respectively, t-test). In all cases, Probe 
performance exceeded chance levels (i.e., 25% for target quadrant, 1% for target area). 
Performance in the more sensitive Learning Set MWM was also similar between SAH 
and sham groups (Figure 15D-E). No significant differences were seen in the Learning Set task 
(p=0.89, omnibus repeated measures ANOVA). No significant differences were seen in Probe 
trial performance: time spent in the target quadrant and in the target area was similar (p=0.26, 
p=0.52, respectively, t-test). Again, Probe performance exceeded chance levels in both groups. 
A total of four SAH mice were disqualified from MWM testing due to an inability to 
complete the MWM: one in Experiment 2 (unable to learn procedural aspects of Cued training), 
two in Experiment 3 (one unable to learn procedural aspects of Cued training; one unable to 
swim due to dense hemiparesis), and one in Experiment 4 (unable to stay above water for the 16 
daily trials). 
In summary, these data demonstrate that, despite reducing SAH mortality and utilizing 
multiple MWM protocols, endovascular perforation SAH causes consistent (albeit mild) 
sensorimotor deficits – but no visuospatial learning or memory deficits – in mice surviving the 
acute post-SAH period. 
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Unbiased stereology 
Brain sections from mice that completed the MWM were examined for cortical cavitation 
consistent with chronic infarction: no clear example was found. In these mice, cortical volume of 
the ipsilateral hemisphere was not significantly reduced (96.9±2.8% of contralateral side, versus 
97.9±3.3% in sham). In the four mice that survived but were excluded from MWM testing, 
cavitation consistent with chronic infarction was seen in only one (data not shown). 
Morphologically intact hippocampal CA1 neurons (ipsilateral to side of SAH) were 
counted via unbiased stereology in mice subjected to the Learning Set MWM in Experiment 4. 
Minimal injury was noted (Figure 17A): neuronal cell counts and spared CA1 volume were 
similar in SAH and sham groups (Figure 17B-C; p=0.88, p=0.90, respectively, t-test). No 
correlation was noted between CA1 neuronal cell counts and MWM performance (Figure 17D; 
p=0.83, Pearson correlation). In the four mice disqualified from MWM testing, mean neuronal 
cell counts were 199±47, similar to those completing the MWM. In total, these data demonstrate 
that endovascular perforation SAH fails to cause significant damage to hippocampal CA1. 
 
Long-term TBI outcome 
In Experiment 5, included as a positive control, mice were subjected to controlled cortical 
impact–TBI or sham surgery. All mice survived (N=10 in each group). TBI mice evinced 
significant neurological deficits (Figure 16A; p<0.001, omnibus repeated measures ANOVA). 
TBI caused significant deficits in the Learning Set MWM (Figure 16B; p=0.0027, omnibus 
repeated measures ANOVA). Probe performance exceeded chance levels in sham mice; by 
contrast, TBI mice performed at or below chance levels (Figure 16C; p<0.00001 versus sham, t-
test, for both target quadrant and target area). TBI caused severe injury in ipsilateral CA1 (Figure 
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17A), ranging from reduction in CA1 thickness (arrow) to near-complete obliteration 
(arrowhead): significantly fewer neuronal cells were counted in CA1 in TBI than in TBI mice 
(Figure 17B; p<0.001, t-test), and CA1 volume was strikingly reduced in TBI compared to sham 
mice (Figure 17C; p<0.001, t-test). A significant correlation was noted between CA1 neuronal 
cell counts and MWM performance (Figure 17E; p<0.001, Pearson correlation). 
 
 
DISCUSSION 
Results of the present study provide strong evidence that, in mice, the endovascular 
perforation SAH model fails to cause long-term learning or memory deficits as assessed by the 
MWM. This is a major experimental limitation, as it is by far the most commonly utilized mouse 
model of SAH owing to its relative ease in development, close recapitulation of the physiological 
events involved with aneurysmal SAH (e.g., arterial perforation, localization of blood in the 
basal cisterns, acute rise in intracranial pressure, and transient global ischemia), and applicability 
to the use of powerful, targeted genetic manipulations. We rigorously examined possible reasons 
for our finding, including high mortality (albeit comparable to the 20–33% reported in rat 
studies74, 76-78), lack of sensitivity of the MWM protocol, and extent of neuronal cell loss in 
hippocampal CA1. We increased survival by modifying post-operative support; moreover, we 
employed different MWM protocols, the standard Place task and the more sensitive Learning Set 
task. Neither manipulation identified MWM deficits. We examined the extent of neuronal cell 
loss in hippocampal CA1, finding that it was inconsistent and did not correlate to MWM deficits. 
As a positive control, we examined controlled cortical impact–TBI, demonstrating reliable CA1 
neuronal cell loss and significant MWM deficits, which are consistent with and extend our past 
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results with this model.166 In total, our results indicate that endovascular perforation SAH in mice 
does not produce demonstrable long-term learning or memory deficits as assessed by the MWM 
and that the cause of this is likely inconsistent neuronal cell loss in CA1. The latter may have 
resulted from significant delayed mortality that preferentially affected mice having the most 
severe neurological deficits and thus most likely to have had significant CA1 neuronal cell loss 
and cognitive deficits. As far as we are aware, this is the first report examining long-term 
neurobehavioral outcome in a mouse model of SAH. 
Cognitive deficits afflict half of SAH survivors51 and are discernable as long as 6 years 
after ictus.168 Such deficits are seen even in patients with “good outcome”: those with a Glasgow 
Outcome Scale of 5 nonetheless have demonstrable deficits in multiple assessments of executive 
function at 6 months.169 These cognitive deficits have major implications with regard to patient-
relevant outcome as they strongly predict long-term morbidity, including poor self-reported 
quality of life, reduced ADLs, impaired instrumental ADLs, and the inability to return to work in 
at least 50% of patients.10 
Though the frequency and gravity of long-term cognitive deficits in SAH patients are 
well documented, their underlying neurophysiological processes have only recently begun to be 
elucidated. Multiple lines of evidence implicate hippocampal impairment as playing a central 
role. First, hippocampal volume is reduced in SAH patients at 1 year, and this reduction 
correlates to performance on visual memory tests170 – a particularly compelling result given the 
well-known central involvement of the hippocampi and other medial temporal lobe structures in 
many forms of declarative memory.171 Second, multiple molecular alterations in the hippocampi 
occur following rat SAH, including loss of synaptic function and long-term potentiation.172, 173 
Third, cognitive deficits have been strongly correlated to hippocampal CA1 neuronal cell 
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number after experimental SAH.73 To be sure, other structural areas may also play a role, 
including left hemispheric lesions,174 reductions in total gray and white matter volume175 (in 
patients), and cortical neuronal cell loss (in rats).73 In total, these data provide substantial 
evidence that hippocampal damage plays a key role in SAH-induced cognitive deficits, but that 
alterations in other brain areas also contribute.  
We thus examined hippocampus-dependent long-term neurobehavioral outcome 
following endovascular perforation SAH in the mouse. Despite attenuating mortality and 
employing two separate protocols of the MWM – the most commonly used metric for cognitive 
outcome in rodents – no significant deficit by any measure was seen after SAH. Most likely, this 
was because of insufficient CA1 neuronal cell loss in long-term SAH survivors. Neuronal cell 
loss following endovascular perforation SAH in mice has only been examined in two previous 
reports, both of which assessed cell death at acute time points and only in cerebral cortex (and 
not in CA1). We documented significant neuronal cell death (as assessed by terminal 
deoxynucleotidyl transferase dUTP nick end labeling, TUNEL) in the ipsilateral parietal cortex 
72 hours post-SAH,141 and Altay and colleagues reported significant TUNEL-positive neuronal 
cell death in the ipsilateral basal cortex 24 hours post-SAH.96 When considered in the context of 
our present results – showing no chronic SAH-induced decrease in morphologically intact CA1 
neurons – these results suggest that some combination of severity or location of injury 
(hippocampus versus cortex, ipsilateral versus bilateral) and timing or method of assessment 
(acute versus chronic, actively dying versus intact neurons) may account for the lack of MWM 
deficits in the endovascular perforation mouse model. 
Another possible explanation for our negative findings is the long-term mortality 
associated with this model. While we succeeded in mitigating delayed mortality by increasing 
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post-SAH support, it nonetheless remained substantial (~20%). It is possible that significant 
neuronal cell loss occurred in the mice that died, a contention substantiated by the strikingly 
greater sensorimotor deficits seen in such mice compared to SAH survivors. If this were the case, 
by assessing neuronal cell survival approximately one month after SAH (as opposed to acutely as 
in previous reports with this model), we would have inadvertently selected against mice with 
quantifiable neuronal cell loss and attendant MWM deficits. 
Others have examined neuronal cell death in alternate mouse models of SAH. Using the 
prechiasmatic injection model, Sabri et al. reported significant TUNEL-positive neuronal cell 
death in ipsilateral middle cerebral artery–territory cortex and hippocampus 48 hours post-
SAH.176 Interestingly, far less neuronal cell death was seen in the hippocampus than in the 
cortex, but it was not specifically quantified in CA1. Following cisterna magna injection of 
oxyhemoglobin, Huang et al. documented TUNEL-positive neuronal cell death in cortex at 24 
and 72 hours,177 but did not specify what area of cortex was assessed and provided no 
quantification. Given the paucity of data regarding the extent and especially the location of 
neuronal cell injury – particularly in CA1, the brain region most implicated in MWM deficits in 
rat SAH73, 172, 173 and rodent TBI178 – it is difficult to predict whether either of these alternative 
mouse models might better recapitulate the long-term cognitive deficits seen in SAH patients. 
In contrast, neuronal cell death and long-term outcomes in rat models of SAH have been 
more thoroughly characterized. Takata and colleagues were the first to report that rats displayed 
significant deficits in the Learning Set MWM following cisterna magna double-injection SAH, 
and that MWM performance correlated with hippocampal and cortical neuronal cell counts.73 
Multiple subsequent reports have documented cognitive deficits in the three most commonly 
used rat models of SAH: cisterna magna injection,73, 75 endovascular perforation,74, 77 and 
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prechiasmatic cistern injection.76, 78 Each of these studies employed the MWM, widely 
considered the gold standard for spatial learning in rodent models of CNS injury;179, 180 Sherchan 
et al. also showed deficits in T maze performance following rat endovascular perforation SAH.77 
Two reports also show treatment effects, of simvastatin75 and minocycline,77 establishing the 
suitability of the MWM as an outcome measure for therapeutic studies in rat SAH. 
Our study has several limitations. First, we assessed only the endovascular perforation 
mouse model of SAH. We chose to examine this model as it is by far the most commonly used 
mouse model of SAH and it faithfully recapitulates the arterial damage, basal subarachnoid 
blood localization, increased intracranial pressure, and transient global ischemia associated with 
aneurysmal rupture in patients 79. However, as delineated above, other mouse models of SAH 
exist, and one may cause MWM deficits. Second, we examined long-term neurobehavioral 
deficits using only the MWM, albeit with two distinct protocols. The MWM is considered to be 
the gold standard for examining spatial deficits after rodent CNS injury, and has been reported to 
show dysfunction in numerous CNS disease models, including vascular disease, TBI, 
developmental disorders, Alzheimer’s disease, AIDS dementia complex, and more. However, 
there are other tests of visuospatial memory, and so we cannot exclude the possibility that 
deficits in our model may be revealed by another measure. Third, we examined a single mouse 
strain. C57BL/6 is one of the most commonly used strains in mouse SAH and has been shown by 
multiple groups to recapitulate numerous short-term sequelae; however, it is possible that, while 
neuronal cell loss and long-term neurobehavioral deficits were absent in this line, other strains 
would demonstrate them. Fourth, we examined morphologically intact neurons rather than 
markers of cell death. This was deliberate, as the processes examined by cell death assays would 
have ended by the time of our assessment. Nonetheless, it is possible that despite not affecting 
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the number of surviving hippocampal neurons, SAH could have had more subtle molecular 
effects.172, 173 This possibility is distinctly unlikely given the absence of MWM deficits (an 
assessment critically dependent on hippocampal function) documented herein. Finally, SAH-
related morality remained at 18% despite significant post-SAH support. It therefore remains 
possible that significant neuronal cell loss and MWM deficits would have occurred in the mice 
that died. 
 
 
CONCLUSIONS 
Our results strongly indicate that the endovascular perforation mouse model of SAH does 
not cause reliable CA1 neuronal cell death and does not produce demonstrable long-term 
neurobehavioral deficits as assessed by the MWM. This is a major experimental limitation, given 
that long-term cognitive deficits in SAH patients have such a profound effect on quality of life to 
the individual and have a similarly significant effect to society with regard to the cost of care and 
loss of productivity related to these patients. Development of an experimental model of SAH-
induced cognitive dysfunction that permits use of genetically modified mice to determine the 
influence of certain genotypes on SAH outcome (e.g., ApoE, haptoglobin, and others), and allow 
targeted mechanistic inquiry, would represent a major advance forward for the field. Until that 
time, however, translational studies employing long-term assessments of outcome – including 
cognitive measures – should likely employ rat models of SAH, aided by the increasing 
availability of genetically modified lines. 
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Table 2: Summary of Experimental Protocols. 
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1 SAH Days 0–3: dex-NS N/A 3 days 7% 
2 SAH Days 0–3: dex-NS Place 23 days 34% 
3 SAH Days 0–7: dex-NS Place 23 days 25% 
4 SAH Days 0–3: amp in dex-NS Days 4–7: dex-NS 
Place (cohort 1) 
Learning Set (cohort 2) 
23 days 
21 days 18% 
5 TBI Days 0–3: amp in dex-NS Days 4–7: dex-NS Learning Set 21 days 0% 
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Figure 12: SAH causes short-term neurological deficits and delayed cerebral vasospasm; long-
term survival after SAH is increased by extended fluid support and antibiotic administration. 
Mice underwent subarachnoid hemorrhage (SAH) or sham surgery and received fluid support for 
3 days (0.5 ml 10% dextrose in normal saline IP twice daily). Mice were casted with gelatin–
India ink on post-surgery day 3; representative images of casted vessels are shown (A). B. 
Cerebral vasospasm was assessed via measurement of the proximal middle cerebral artery. 
Neurobehavioral assessment was performed on post-surgery days 1-3 via sensorimotor scoring 
(C). Data indicate mean±SEM. *p<0.05 vs. sham by t-test (B) or repeated measures ANOVA and 
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Newman-Keuls multiple comparison test (C) D. SAH was induced and mortality was recorded 
with three regimens of post-surgical support: post-surgical injections of dextrose-saline solution 
for 3 days (dex-NS–3d) or 7 days (dex-NS–7d), or ampicillin in dextrose-saline for 3 days post-
surgery followed by another four days of dextrose-saline (amp + dex-NS–7d). No sham-operated 
control (sham) died. 
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Figure 13: SAH followed by 3 days of fluid support causes deficits in neurological outcome but 
not in the Place Morris water maze.  
Mice underwent subarachnoid hemorrhage (SAH) or sham surgery and received fluid support for 
3 days (0.5 ml 10% dextrose in normal saline IP twice daily). Neurobehavioral assessment was 
performed on post-surgery days 1-3, 7, and 12 via sensorimotor scoring (A). Long-term 
neurocognitive outcome was performed on post-surgical days 13-22 by the Place Morris water 
maze (B). Data indicate mean±SEM. *p<0.05 vs. sham, #p<0.05 vs. SAH (surv) by repeated 
measures ANOVA and Newman-Keuls multiple comparison test. C. A 30-second Probe trial was 
performed 24 hours after the Place task; time spent in the target quadrant and in the previous 
location were determined. The dashed line denotes chance performance; data represent 95% 
confidence interval of the mean. NS P > 0.05 vs. sham by t-test. SAH-mort, SAH mortality 
group. 
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Figure 14: SAH followed by 7 days of fluid support causes deficits in neurological outcome but 
not in the Place Morris water maze. 
Mice underwent subarachnoid hemorrhage (SAH) or sham surgery and received fluid support for 
7 days (0.5 ml 10% dextrose in normal saline IP twice daily). Neurobehavioral assessment was 
performed on post-surgery days 1-3, 7, and 12 via sensorimotor scoring (A). Long-term 
neurocognitive outcome was performed on post-surgical days 13-22 by the Place Morris water 
maze (B). Data indicate mean±SEM. *p<0.05 vs. sham, #p<0.05 vs. SAH (surv) by repeated 
measures ANOVA and Newman-Keuls multiple comparison test. C. A 30-second Probe trial was 
performed 24 hours after the Place task; time spent in the target quadrant and in its previous 
location were determined. The dashed line denotes chance performance; data represent 95% 
confidence interval of the mean. NS P > 0.05 vs. sham by t-test. SAH-mort, SAH mortality 
group. 
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Figure 15: SAH followed by 7 days of fluid support plus antibiotic prophylaxis causes deficits in 
neurological outcome but not in the Place or Learning Set Morris water maze. 
Mice underwent subarachnoid hemorrhage (SAH) or sham surgery and received antibiotics for 3 
days (50 mg/kg ampicillin IP once daily, first dose prior to surgery) followed by fluid support on 
days 4-7 (0.5 ml 10% dextrose in normal saline IP twice daily). Neurobehavioral assessment was 
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performed on post-surgery days 1-3, 7, and 12 via sensorimotor scoring (A). Long-term 
neurocognitive outcome was performed on post-surgical days 13-22 by the Place Morris water 
maze (B). A 30-second Probe trial was performed 24 hours after the Place task; time spent in the 
target quadrant and in the previous location were determined (C). A separate cohort of mice was 
subjected to the Learning Set Morris water maze on post-surgical days 13-21 (D). A 30-second 
Probe trial was performed 16 hours after the completion of the previous day’s task; time spent in 
the target quadrant and in the previous location were determined (E). A,B,E: Data indicate 
mean±SEM. *p<0.05 vs. sham, #p<0.05 vs. SAH (surv) by repeated measures ANOVA and 
Newman-Keuls multiple comparison test. C,E: The dashed line denotes chance performance; 
data represent 95% confidence interval of the mean. NS P > 0.05 vs. sham by t-test. SAH-mort, 
SAH mortality group. 
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Figure 16: Experimental TBI causes significant deficits in neurological outcome and in the 
Learning Set Morris water maze. 
Mice underwent traumatic brain injury (TBI) or sham surgery and received antibiotics for 3 days 
(50 mg/kg ampicillin IP once daily, first dose prior to surgery) followed by fluid support on days 
4-7 (0.5 ml 10% dextrose in normal saline IP twice daily). Neurobehavioral assessment was 
performed on post-surgery days 1-3, 7, and 12 via sensorimotor scoring (A). Long-term 
neurocognitive outcome was performed on post-surgical days 13-21 by the Learning Set Morris 
water maze (B). A 30-second Probe trial was performed 16 hours after the completion of the 
previous day’s task; time spent in the target quadrant and in the previous location were 
determined (C). A,B: Data indicate mean±SEM. *p<0.05 vs. sham by repeated measures 
ANOVA and Newman-Keuls multiple comparison test. C: The dashed line represents chance 
performance; data represent 95% confidence interval of the mean. *p<0.05 vs. sham by t-test. 
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Figure 17: Histological damage in CA1 correlates to performance in the Learning Set task 
following experimental TBI but not SAH. 
Following completion of the Learning Set task, mice from Experiments 4 and 5 were sacrificed 
and their brains were sliced. Representative histological images of cresyl violet–stained coronal 
sections are shown (A). Scale bar = 500 µm. Traumatic brain injury (TBI) – but not subarachnoid 
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hemorrhage (SAH) – caused significant loss of morphologically intact neurons in hippocampal 
CA1 (B) and in ipsilateral CA1 volume (C). Data represent mean±SEM. *p<0.05 vs. sham TBI 
by t-test. NS P > 0.05 vs. sham by t-test. Scatter plots relating neuronal counts to mean distance 
swum in the Morris water maze following SAH (D) and TBI (E). Dashed lines represent 95% 
confidence bands. Pearson correlations are shown, NS P > 0.05. 
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FUTURE DIRECTIONS AND CONCLUSIONS 
Delayed cerebral ischemia (DCI) remains a major source of morbidity in patients with 
aneurysmal subarachnoid hemorrhage (SAH). Moreover, cognitive dysfunction is the primary 
driver of poor long-term outcome in SAH survivors; modeling such deficits preclinically is thus 
key for mechanistic and translational investigation. We thus sought to determine whether 
activating innate neurovascular protective mechanisms by conditioning could reduce SAH-
induced dysfunction and, if so, by which molecular mediators. We found that endogenous 
protective mechanisms against contributors to DCI exist and are powerful; can be induced by 
conditioning stimuli, including with clinically relevant parameters; and depend critically on 
endothelial nitric oxide synthase (eNOS) and hypoxia-inducible factor 1α (HIF-1α). As such, a 
conditioning strategy may represent a novel therapeutic approach to mitigate SAH-induced DCI 
and its resultant morbidity and mortality. To further assess the translational potential of such 
strategies, we sought to model long-term neurobehavioral outcomes in our preclinical model. 
Unfortunately, we were unable to identify robust or consistent SAH-induced deficits in the most 
commonly used mouse model of SAH, endovascular perforation, using the gold standard of 
spatial learning, the Morris water maze (MWM). As such, preclinical studies examining the 
efficacy of interventions on long-term outcomes should employ rat models, as multiple groups 
have documented significant SAH-induced neurobehavioral deficits in them. 
Our results raise several questions that warrant further investigation. Experiment 1, a 
proof-of-concept study demonstrating that hypoxic PC protects against SAH-induced DCI, 
strongly supports a causal role for eNOS-derived nitric oxide (NO) in the phenotype. However, 
we did not directly assess whether the other isoforms of NOS (iNOS and nNOS) are also 
necessary for the protection afforded. This is unlikely given that PC had no significant effect on 
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the expression of either, in contrast to the increase in eNOS expression we documented. 
Nonetheless, the possibility remains that the neurovascular protective phenotype would be 
reversed in mice deficient for iNOS or nNOS similar to what we documented in eNOS-null mice. 
Second, while we demonstrated that hypoxic PC significantly reduced SAH-induced DCI 
and neurological deficits, we did not assess its effect on early brain injury (EBI). Given the 
multifactorial nature of PC-induced protection across experimental modalities, it is likely that the 
neurovascular effects extends to BBB disruption and neuronal cell death, the principal 
contributors to EBI. Similarly, we did not assess whether hypoxic PC attenuates SAH-induced 
inflammation. Such studies would support the notion that PC, by impacting multiple injurious 
processes, might succeed in improving SAH outcomes where other, more selective interventions 
have failed.  
Finally, the paradigm used in Experiment 1 is not clinically relevant for two reasons. 
First, PC was administered prior to SAH. This was by design, as we were proving the concept 
that SAH-induced vasospasm was amenable to a strategy to boost endogenous protection. 
Nonetheless, given the inherent unpredictability of aneurysm rupture, it is unrealistic to expect to 
employ PC in the SAH population. Similarly, the use of hypoxia as the PC stimulus is highly 
unlikely to be used clinically (though it is possible that pharmacologic agents that mimic its 
effects could be employed). Again, though, choosing it was by design due to our collaborator Dr. 
Gidday’s experience with the paradigm. 
Experiment 2 was conceived in part to address the translational shortcomings of the 
proof-of-concept study: the conditioning stimulus was delivered after SAH rather than before, 
and the stimulus employed is a standard-of-care anesthetic in SAH patients. Nonetheless, these 
studies raise interesting questions that warrant further investigation. Broadly, these fall under 
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three categories: (1) further elaborating the breadth of the protection afforded by isoflurane 
postconditioning; (2) further delineation of its underlying mechanism, in particular the cause of 
HIF-1α up-regulation by isoflurane and the critical downstream effectors; and (3) cross-
validation as recommended by the Stroke Therapy Academic Industry Roundtable’s criteria for 
translational studies.81 
Regarding the breadth of the protective phenotype: though we expanded our 
consideration of SAH-induced DCI relative to Experiment 1, there are nonetheless several other 
SAH-induced injurious processes that we did not assess. Regarding DCI, we assessed the effect 
of isoflurane postC not just on cerebral vasospasm (as in Experiment 1) but also cortical 
microthrombosis and microvessel dysfunction. We did not, however, assess its effect on cortical 
spreading depression. To our knowledge there are no published reports documenting cortical 
spreading depression (CSD) in mouse SAH, though one prominent CSD researcher has 
attempted to assess it with minimal success (Dr. Cenk Ayata, personal communication to GJZ). 
Nonetheless, CSD could be assessed as part of our cross-validation studies in other models in 
which it has been documented, specifically in the cat181 or more likely the rat182, 183. 
Future investigation of the breadth of postC-induced protection should also examine 
processes other than DCI. Altay and colleagues showed that two contributors to EBI (cerebral 
edema95 and neuronal cell death96) are attenuated by isoflurane postconditioning. However, other 
SAH-induced deleterious processes include damage to axonal projections, glial cells, and even 
extra-cerebral organs,184 have not been examined in the context of endogenous protection. 
The prospect of a conditioning-based intervention to attenuate damage to glial cells and 
white matter is particularly intriguing, for several reasons: (1) multiple groups have documented 
such injury, both clinically and in animal models of SAH. Petzold and colleagues documented 
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increased CSF levels of neurofilament in SAH patients.185 In preclinical studies, Sabri et al. 
found astrocyte apoptosis in the hippocampus, cerebral cortex and brain stem following cisterna 
magna–injection SAH in the dog.186 We recently documented that axonal injury is widespread 
following endovascular perforation SAH in the mouse.187 (2) Glial cell death and dysfunction 
have been implicated in the pathogenesis of DCI (for review, see Mutch, 2010188). Astrocytes are 
connected via gap junctions and thereby form a functional syncytium that is critical for buffering 
extracellular potassium and glutamate. Ischemia-induced acidosis uncouples astrocytes, 
decreasing their buffering capacity and thus the ability of nearby neurons to repolarize, thereby 
contributing to CSD. Moreover, increased intracellular calcium is seen in astrocytic end-foot 
processes due to increased 20-HETE and decreased NO, which can result in increased vasomotor 
tone and thus contribute to microvessel dysfunction. (3) Glial cells and white matter have been 
shown to be amenable to conditioning-based intervention. Our collaborator Dr. Gidday has 
demonstrated that retinal ganglion cell axonal injury in a mouse model of glaucoma was 
decreased by repetitive hypoxic PC.146, 189 Other groups have shown that heat-stress PC 
improved MWM performance and maintained LTP following diffuse axonal injury190 and that 
hyperbaric oxygen PC attenuated axonal injury following spinal cord injury in the rat.191 Given 
this greater appreciation for the role of the neurovascular unit in SAH-induced pathology, 
recognizing the pleiotropic effects of conditioning-based therapies raises the exciting possibility 
that such interventions could have wide-ranging salubrious effects. 
Second, beyond examining the pleiotropic effects of isoflurane postconditioning, future 
studies should also consider its underlying molecular and cellular mechanisms. Experiment 2 
established HIF-1α as critical mediator of the vasculoprotective phenotype we documented. 
However, we did not examine the mechanism by which isoflurane up-regulated HIF-1α, nor did 
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we establish which downstream effectors were responsible for the observed resistance of the 
brain to SAH-induced dysfunction (see Chapter 2 Discussion). Moreover, cell-specific analysis 
will be valuable given the varying pathophysiological processes responsible for large-artery 
vasospasm, cortical microthrombosis and microvessel dysfunction.  
Third, cross-validation studies will be critical to translating our preclinical findings to the 
SAH patient population. Our studies have employed rigorous experimental design, including 
calculation of power and sample sizes, a priori determination of inclusion/exclusion criteria, 
randomized allocation of animals, blinded assessment, and disclosure of potential conflicts of 
interest – a standard of rigor that puts them, disappointingly, in the minority of animal studies.192 
To date, we have utilized young, healthy male mice. As recommended by the Stroke Therapy 
Academic Industry Roundtable,81 follow-up studies should cross-validate these initial findings in 
several other experimental cohorts, including: females; aged animals; animals with commonly 
comorbid conditions (in SAH, hypertension, diabetes, and cigarette smoking); employing other 
experimental models, both in terms of method of induction as well as animal, particularly in 
gyrencephalic species; and assessing the additive effects of the intervention in animals given 
standard-of-care drugs (e.g. the calcium-channel blocker nimodipine). Performing such 
experiments would substantiate the translational potential of isoflurane postconditioning into a 
patient population. 
Fourth, collaborating with independent laboratories to replicate certain key findings 
would further substantiate our conclusions to date. Though most isoflurane postconditioning 
papers report a protective effect, regardless of the disease being modeled, this almost certainly 
represents publishing bias. Even when negative results are published, synthesizing them with 
positive papers is typically complicated by key methodological differences among groups. For 
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example, in the context of experimental intracerebral hemorrhage (ICH), Esposito and colleagues 
found no beneficial effect of post-ICH isoflurane,193 in contrast to Khatibi et al.155 Reconciling 
these broadly different results is challenging in light of differences in species employed and 
method of induction (respectively rat versus mouse, injection of collagenase versus of 
autologous blood). Such problems to interpretation could be minimized through direct 
collaboration with other groups: replicating key results would increase confidence in their 
veracity and strengthen the case for further translational studies.  
Finally, future studies should assess delayed outcomes (at least 2-3 weeks after SAH), 
both behavioral and histologic. This emphasis on long-term outcome led us to perform 
Experiment 3. Unfortunately, despite reducing SAH mortality and employing two distinct 
versions of the gold-standard assessment for rodent learning and memory, we concluded that the 
endovascular perforation SAH in the mouse fails to cause demonstrable long-term MWM 
deficits, likely due to unreliable CA1 neuronal cell death. Given the frequency and severity of 
long-term cognitive deficits in SAH patients, further efforts are warranted. One possibility is to 
examine whether experimental parameters employing the mouse, which has myriad genetically 
modified lines, can be altered to detect neurobehavioral deficits. As discussed (see Chapter 3 
Discussion), other mouse strains or methods of SAH induction could be employed, or other 
outcomes measures assessed. However, given that MWM deficits are seen in the rat in the three 
most commonly employed SAH models (endovascular perforation, cisterna magna injection and 
prechiasmatic injection), future studies should assess the effect of conditioning strategies on 
long-term neurobehavioral and histologic outcomes in the rat. 
In summary, we demonstrate that conditioning strategies can reduce SAH-induced DCI. 
Significantly, protection was seen not just in proof-of-concept studies (employing pre-SAH 
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hypoxia) but also with a clinically relevant stimulus (isoflurane) delivered at a clinically relevant 
dose and time point. Moreover, HIF-1α and eNOS were identified as critical mediators of the 
neurovascular protection. Regarding cognitive outcomes after SAH, a significant source of long-
term morbidity, we found that the endovascular perforation mouse model of SAH does not cause 
reliable CA1 neuronal cell death and does not produce demonstrable long-term neurobehavioral 
deficits as assessed by the MWM. 
We thus conclude that conditioning strategies represent a promising therapeutic approach 
to combat SAH-induced DCI. Future studies should further delineate the molecular pathways 
responsible for this protection, as well as the impact on long-term neurobehavioral deficits 
employing rat models. 
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